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Chapter 1. 
General Introduction 
 
 
 
The dawn of marine natural product chemistry goes back to the 1950s with the 
discovery of nucleoside analogues from a marine sponge.1 Continuing study of 
metabolites of marine organisms led to the discovery of a large number of fascinating 
bioactive compounds from various marine flora and fauna, including sponges, corals, 
ascidians, sea weeds, and marine bacteria.2 Marine sponges are known to be particularly 
rich sources of bioactive metabolites, and more than 25,000 metabolites have been 
identified so far.3 The driving force that motivates scientists to discover new compounds 
from marine organisms is their structural diversity and unique bioactivity.4  
The potential of marine natural products has been verified as leads for drug 
development, and the importance of identification of novel bioactive compounds from 
marine organisms has been increasing. Recent technological breakthroughs permitted us 
to access deeper fields of marine natural products chemistry and accelerated the 
discovery of bioactive marine natural products.3 For example, development of 
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mass-sensitive NMR techniques enabled the structure analysis of submilligram samples 
and made it easier to access rare minor constituents of marine organisms.5 Moreover, 
improvements of sensitivity of mass spectrometer resulted in the development of new 
research fields: metabolomics and molecular networking of natural product.6, 7 The 
innovative research of X-ray crystallography demonstrated its potential as new effective 
methodology for the structure elucidation of small molecules.8 A technological 
improvements in collecting marine organisms made it possible to access uncommon 
marine organisms inhabiting at deep-sea or unexplored sea area.9 Consequently, the 
number of newly isolated compounds from marine organisms per decade continues 
increasing. 
Together with the technological breakthroughs and renaissance of marine 
natural product chemistry, new scientific fields are evolving from marine natural 
product chemistry; genetics, chemical biology, chemical genetics and chemical 
ecology.10 These translational researches activate the marine natural products chemistry, 
and attract a great deal of attention to marine natural products as a tool for the scientific 
research and leads for drug discovery.11 
Recently, several marine natural product derived drugs have been approved by 
the Food and Drug Administration (FDA) and European Agency for the Evaluation of 
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Medicinal Products (EMA), and approximately 20 compounds are either in Phase I, 
Phase II, or Phase III clinical trials.12 Most of these therapeutically important marine 
natural products have been discovered through cell-based assays (Table 1-1). The detail 
of several representative marine natural products and marine-derived drugs are 
introduced below.    
 
Table 1-1. List of marine-derived drug leads identified by cell-based assay 
Compound Name Chemical Class Marine Organisms 
Ecteinascidin 74313 Alkaloid Tunicate 
Halichondrin B14 Macrolide Sponge 
Dolastatin 1015 Peptide Bacterium 
Dolastatin 1515 Peptide Bacterium 
Kahalalide F16 Depsipeptide Mollusk 
Plitidepsin17 Depsipeptide Tunicate 
Jorumycin18 Alkaloid Nudibranch 
Pseudopterosin19 Diterpene glycoside Soft coral 
Bryostatin-120 Polyketide Bryozoa 
Hemiasterlin21 Tripeptide Sponge 
Salinosporamide A22 β-Lactone-γ-lactone Bacterium 
Bengamide B23 Amino acid derivative Sponge 
Discodermolide24 Lactone Sponge 
Spisulosine25 Lipid Mollusk 
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Approved marine-derived anticancer drugs 
 
Spongothymidine was isolated from the Caribbean marine sponge Tethyacrypta 
in the 1950s, and consists of an arabinose sugar and thymine.1 Spongothymidine and 
cytarabine, a synthetic analogue of spongothymidine, are nucleoside analogues,26 and 
they inhibit DNA polymerase and DNA synthesis by competing with cellular 
nucleoside.27 Cytarabine was approved as the anticancer drug by FDA in 1969, the first 
marine-derived drug, and used in the treatment of acute lymphocytic leukemia, acute 
myelocytic leukemia and blast and meningeal leukemia.28 
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A tetrahydroisoquinoline alkaloid, trabectedin, another name being 
ecteinascidin 743, was isolated from the Caribbean tunicate, Ecteinascidia turbinate.13 
Trabectedin is composed of three tetrahydroisoquinoline units and 10-membered lactone 
ring bearing a thioether bridge. This compound exhibits potent toxicity against a broad 
spectrum of tumor types. The mechanism of action of trabectedin is still unclear, but it 
is known to form a covalent bond to the DNA minor groove, and interacts with the 
nucleotide excision repair system.29 It induces mitotic arrest and apoptosis. Trabectedin 
inhibits the gene expression of MDR1 gene, which encodes a P-glycoprotein, and keeps 
the drug susceptibility of tumor cells.30 It was approved as the anticancer drug for 
ovarian cancer. 
 
 
Trabectedin (ET-743) 
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Halichondrin B, a polyether macrolide was originally isolated from the marine 
sponge Halichondria okadai in 1986.14 It showed very potent cytotoxicity against 
L1210 murine leukemia cells with an IC50 value of 0.3 nM, and induced cell cycle arrest 
at G2/M phase by inhibition of tubulin polymerization. Halichondrin B is known to 
interact with vinca domain of tubulin, a region located at the interface of tubulin 
heterodimers.31 Its molecular mechanism of action is distinct from other 
tubulin-targeting agents such as taxane and vincas.32 Eribulin mesylate, a structurally 
simplified synthetic Halichondrin B analogue, was developed by Eisai.33 Eribulin 
mesylate was approved by FDA for the treatment of metastatic breast cancer.34 
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 Dolastatin 10 was discovered from the sea hare Dolabella auricularia as a 
potent antineoplastic compound in 1972.15 The cyanobacteria Symploca hydnoides and 
Lyngbya majuscule were later revealed to be the producers of dolastatin 10.35 Dolastatin 
10 binds to the vinca domain of tubulin and inhibits the assembly of tubulin.31, 32 
Investigation of the structure activity relationship of synthetic analogues of dolastatin 10 
resulted in the development of monomethyl auristatin E.36 Seattle Genetics developed a 
technology to couple this compound to monoclonal antibodies.37 This antibody-drug 
conjugate, named brentuximabvedotin binds to the antigen, CD30, expressed on the 
cancer cell surface, and monomethyl auristatin E exhibits toxicity against cancer cells. 
Brentuximabvedotin was approved by FDA in 2011 for the treatment of Hodgkin’s 
lymphoma or systemic anaplastic large cell lymphoma. 
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Marine-derived anticancer drugs in clinical trials 
 
 Plitidepsin, didemnin B homologue, is a depsipeptide isolated from the 
Mediterranean Sea tunicate Aplidium albicans.17 The chemical structure of plitidepsin is 
very close to that of didemnin B, the only difference being in the lactate residue.38 It 
shows potent antitumor activity against SK-MEL-28, human melanoma cells, with an 
IC50 value of 12 nM. It induces cell cycle arrest at G1 and G2/M phase and apoptosis by 
the activation of Rac1/ c-Jun NH2-terminal kinase pathway.
39 It has proceeded to the 
Phase I and II clinical trials in combination with other active agents, bortezomib and 
dexamethasone for the treatment of patients with relapsed and refractory myeloma. 
 
 
 
 
 
 
Plitidepsin (Aplidin) 
 
9 
 
 Hemiasterlin is a cytotoxic tripeptide, originally isolated from the sponge 
Hemiasterella minor.40 E7974 is the synthetic analogue of hemiasterlin developed by 
Eisai Inc. Substitution of the N-terminal amino acid residue of hemiasterlin conquered 
the susceptibility of p-glycoprotein mediated efflux and enhanced the potency.41 E7974 
exhibits antimitotic activity, disruption of spindle formation, and induction of caspase-3 
mediated apoptosis. It binds to the β-tubulin and inhibits the tubulin polymerization.41 
E7974 has been assessed in the Phase I clinical trial for the treatment of the colon 
cancer.42 
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 Cell-based assay has advantages of its reproducibility and simplicity.43 It is 
robust enough to be applied to the high throughput screening, and it can screen 
membrane permeable compounds, targeting a wide variety of the cellular components.44 
A variety of cell-based assays are developed that measure cell proliferation, toxicity, 
activation of specific signaling pathways and changes in morphology.45 Cell viability 
assay is one of the basic and effective techniques to evaluate cytotoxicity and 
anti-proliferative activity. Furthermore, cell viability assays against a panel of multiple 
cancer cell lines can predict the molecular mechanism of the bioactive compounds.46 
Reporter gene assays, which screen bioactive compounds that modulate the expression 
level of the specific gene, is sensitive enough to be applied for the high-throughput 
screening of the compound libraries.47 Cell morphology-based assays can identify 
bioactive compounds modulating cellular processes, and provide insights into the 
molecular mechanisms of them.48 Therefore, I searched for novel sponge metabolites 
that showed potent bioactivity against cancer cells by using cell-based assays. 
The subjects described in this doctoral thesis are the studies on the novel 
bioactive marine natural products discovered through cell-based assays. Second chapter 
dscribes the studies of cytotoxic acetylenes, (-)-durynes and miyakosynes. Third chapter 
deals with the study of cytotoxic macrolactams, poecillastrin C and its analogue. And 
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the fourth chapter is concerned with the identification of the cell cycle arrest inducers 
discovered through the time-lapse imaging of HeLa/Fucci2 cells. 
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Chapter 2 
Cytotoxic acetylenes isolated from a deep-sea marine sponge Petrosia sp. 
 
 
2.1. Isolation and structure elucidation of (-)-durynes and miyakosynes. 
 
2.1.1. Introduction 
Linear acetylene compounds are prominent constituents of the order 
Haplosclerida.1 Sponge-derived linear acetylenes share the terminal acetylene moiety 
consisting of a terminal alkyne, a secondary hydroxyl group, and an olefin. Even though 
their molecular mechanisms are yet to be disclosed, their diverse biological activities, 
including antitumor, antimicrobial, antifungal, and antiviral activities are of interest for 
the new drug development.2 
In the course of the cytotoxicity screening, the crude extract of a deep-sea 
marine sponge Petrosia sp. exhibited potent activity against HeLa human cervical 
carcinoma cells. Bioassay-guided fractionation of the extract afforded two groups of 
acetylene compounds, (-)-durynes and miyakosynes. Duryne was originally isolated 
from the Bahamian sponge Cribrochalina dura,3 and its absolute configuration was 
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determined by the total synthesis.4 In this study, we isolated the enantiomer of duryne, 
termed (-)-duryne (2-1), and its homologues (-)-duryne B-F (2-2 – 2-6), and 
miyakosynes A-F (2-7 – 2-12). (-)-Durynes consisted of one or two double bonds 
around the center of the molecules, whereas miyakosynes had a branched methyl 
instead of the olefin. In this chapter, isolation and structure elucidation of the (-)-duryne 
(2-1), (-)-durynes B-F (2-2 – 2-6), and miyakosynes A-F (2-7 – 2-12) are described 
below. 
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2.1.2. Results and Discussion 
The sponge Petrosia sp. was collected by a remotely operated vehicle at 
Miyako sea-knoll. The sponge specimen was extracted with EtOH and MeOH/CHCl3 
(1:1), and the combined extracts were concentrated and partitioned between CHCl3 and 
H2O. The CHCl3 layer was further partitioned between 90% MeOH and n-hexane. 
Bioassay-guided fractionation of the 90% MeOH fraction by ODS column 
chromatography, silica gel column chromatography, and reversed-phase HPLC afforded 
twelve cytotoxic compounds (2-1 – 2-12).  
Compound 2-1, which analyzed for C30H48O2 by HRESIMS, exhibited 
1H 
NMR signals characteristic of the terminal structure of sponge-derived acetylenes, [δ 
2.57 (d, J=2.1 Hz; H-1, H-30), δ 4.84 (brd, J=6.4 Hz; H-3, H-28), δ 5.61 (dd, J=15.1, 
6.4 Hz; H-4, H-27), and 5.92 (dt, J=15.1, 6.9 Hz; H-5, H-26)]. A literature search 
showed that the 1H and 13C NMR data of 2-1 (Table 2-1) were identical with those of 
duryne and the position of the central olefin was confirmed by tandem FABMS (Figure 
2-1). However, an opposite sign with a similar magnitude for the specific rotation ([α]D 
= -19) showed that 2-1 was the enantiomer of the previously reported duryne ([α]D = 
+29).3,4 The modified Mosher’s analysis of 2-1 supported this assignment (Figure 2-2).5 
Therefore, we named 2-1 was firmly established to be (-)-duryne.6 
16 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1. Key tandem FABMS fragmentationsfor 2-1 – 2-6 by using the [M+Li]+ ion as the 
precursor. 
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2-1a: R=(R)-MTPA, 2-1b: R=(S)-MTPA 
Figure 2-2. Modified Mosher analysis for 2-1. Δδ (δS-δR) values are shown. 
 
(-)-Duryne B (2-2) had the molecular formula of C32H52O2 as assigned by 
HRESIMS. The1H and 13C NMR spectra of 2-2 were identical with those of 2-1 except 
for the integration of the methylene region (Table 2-1), suggesting that they differ only 
in the length of the aliphatic chains. The position of the Z-olefin in the middle of the 
chain was assigned by tandem FABMS to be between C-15 and C-16 (Figure 2-1). The 
geometry of the Δ15-double bond was assigned by the chemical shifts of 27.4 ppm for 
C-14 and C-17.7 The positions of the double bonds were confirmed by ozonolysis with 
oxidative work-up, which gave FABMS ions at m/z 215 and 243 [M-H]-, consistent with 
the formation of undecanedioic acid and tridecanedioic acid, respectively (Scheme 2-1). 
The configurations of the two secondary alcohols were both determined to be R by the 
modified Mosher’s method.5 
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Scheme 2-1. Ozonolysis of 2-2 – 2-6. 
 
 (-)-Durynes C-E (2-3 - 2-5) had molecular formulas of C32H50O2, C34H54O2, 
and C36H58O2, respectively, as assigned by HRESIMS. The 
1H NMR data of 2-3 - 2-5 
were identical with those of 2-1, except for doubled olefinic and allylic proton peaks 
representing the central double bonds and an increased methylene peak at δ 1.27-1.34, 
suggesting that 3-5 have longer aliphatic chains and one additional double bond in their 
chains (Table 2-2). The geometries of the olefins in the middle of the chain in 2-3 - 2-5 
were all assigned as Z judging from the chemical shifts of the allylic carbons.7 The 
locations of the two Z-olefins were assigned by tandem FABMS to be Δ11,17 for 2-3, 
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Δ13,19for 2-4, and Δ15,21 for 2-5 (Figure 2-1). These assignments were confirmed by the 
ozonolysis experiments (Scheme 2-1). Ozonolysis of 2-3, 2-4, and 2-5 followed by 
oxidative work-up afforded common FABMS ion peaks at m/z 145 and 215 which 
suggested the formation of adipic acid and undecanedioic acid, respectively. Additional 
ions were observed at m/z 159 and m/z 187 in the ozonolysis products of 2-3 and 2-4, 
respectively, consistent with the formation of heptanedioic acid and nonanedioic acid. 
The absolute configurations of the secondary alcohols in the three compounds were all 
determined as R by the modified Mosher’s method.5 
HRESIMS showed that (-)-duryne F (2-6) was an isomer of 2-4. The structure 
of one end was identical with those in the other compounds as judged from the 1H and 
13C NMR data (Table 2-1), whereas in the other end, an acetylenic proton (δ 3.14, J=2.5 
Hz, H-32) was coupled to a Z-olefinic proton (δ 5.54, J=11.0, 2.5 Hz; H-30) which was 
then coupled to another olefinic proton (δ 6.00, J=11.0, 8.9 Hz; H-29). This latter proton, 
H-29, was further coupled to an oxymethine proton (δ 4.68, H-28), indicating a 
rearranged terminus relative to the commonly observed motif. There was a degenerate 
olefinic signal integrating for 2H, which was assumed as a Z-olefin in the middle of the 
chain. The Z-geometry was again assigned by the chemical shifts of the allylic carbons.7 
Tandem FABMS data were not sufficient to locate the double bond, because it was not 
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possible to distinguish the two termini by the MS data. Again we resorted to an 
ozonolysis experiment which afforded a reaction mixture with FABMS ion peaks at m/z 
215 and 273, consistent with the formation of undecanoic acid and 
2-hydroxytetradecanoic acid, respectively, demonstrating the location of the double 
bond between C-15 and C-16 (Scheme 2-1). The absolute configuration was determined 
to be 3R, 28S by the modified Mosher’s method.5 
 
Table 2-1. 1H and 13C NMR data of (-)-Duryne (2-1), (-)-Duryne B (2-2), and 
(-)-Duryne F (2-6) in CDCl3. 
 
  
position δC
a δH (J  in Hz) position δC
b δH (J  in Hz) position δC
b δH (J  in Hz)
1, 30 74.1 2.57, d (2.1) 1 73.9 2.57, d (2.1) 1 74.1 2.57, d (2.1)
2, 29 83.5 2 83.4 2 83.4
3, 28 63 4.84, d (6.4) 3 62.8 4.84, brd (6.2) 3 62.8 4.84, brd (6.2)
4, 27 128.3 5.61, dd (15.1, 6.4) 4 128.3 5.61, dd (15.3, 6.2) 4 128.1 5.62, dd (15.1, 6.2)
5, 26 134.8 5.92, dt (15.1, 6.9) 5 134.5 5.92, dt (15.3, 6.9) 5 134.4 5.92, dt (15.1, 6.9)
6, 25 32.1 2.07, m 6 31.9 2.07, m 6 31.8 2.07, m
7, 24 30.0
c
1.40, m 7 28.7 1.40, m 7 28.9 1.40, m
8-12, 19-23 29.4-29.8c 1.27-1.30, m 8-13 28.7-29.7 1.27-1.36 8-13 28.7-30.0 1.27-1.34
13, 18 29.0c 1.32, m 14 27.4 2.02, m 14 27.3 2.01, m
14, 17 27.4 2.02, m 15 129.9 5.35, m 15 129.9 5.36, m
15, 16 129.9 5.35, m 16 129.9 5.35, m 16 129.9 5.36, m
17 27.4 2.02, m 17 27.3 2.01, m
18-25 28.7-29.7 1.27-1.36 18-26 28.7-30.0 1.27-1.34
26 28.7 1.40, m 27α 36.3 1.63, m
27 31.9 2.07, m 27β 1.52, m
28 134.5 5.92, dt (15.3, 6.9) 28 70 4.68, m
29 128.3 5.61, dd (15.3, 6.2) 29 147.5 6.00, dd (11.0, 8.9)
30 62.8 4.84, brd (6.2) 30 108.7 5.54, dd (11.0, 2.5)
31 83.4 31 82.4
32 73.9 2.57, d (2.1) 32 79.5 3.14, d (2.5)
(-)-duryne (2-1) (-)-duryne B (2-2) (-)-duryne F (2-6)
a 13
C NMR spectrum was measured at 150 MHz. 
b
Chemical shifts were assigned from the HSQC data.
c
Assignments with the same superscript in the same column may be interchangeable.
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Table 2-2. 1H and 13C NMR data of (-)-Duryne C-E (2-3 - 2-5) in CDCl3. 
 
 
  
position δC
b δH (J  in Hz) position δC
a δH (J  in Hz) position δC
b δH (J  in Hz)
1 73.9 2.57, d (2.1) 1 74.1 2.57, d (2.1) 1, 36 74.1 2.57, d (2.2)
2 83.3 2 83.6 2, 35 83.2
3 62.8 4.84, brd (6.2) 3 62.9 4.84, brd (6.2) 3, 34 62.8 4.84, brd (6.2)
4 128.4 5.61, dd (15.1, 6.2) 4 128.6 5.61, dd (15.1, 6.2) 4, 33 128.2 5.61, dd (15.1, 6.2)
5 134.5 5.92, dt (15.1, 6.9) 5 134.7 5.92, dt (15.1, 6.9) 5, 32 134.5 5.93, dt (15.1,6.9)
6 31.9 2.07, m 6 32.1 2.07, m 6, 31 31.9 2.07, m
7 28.7 1.40, m 7 29 1.40, m 7, 30 28.7 1.40, m
8 29.1-29.4 1.28-1.33 8-10 29.3-29.9 1.28-1.32 8-12, 25-29 28.7-29.7 1.27-1.34
9 29.4 1.36,m 11 29.5 1.36, m 13, 24 29.4 1.36, m
10 27.1 2.02, m 12 27.1 2.03, m 14, 23 27.1 2.03, m
11 130 5.36, m 13 129.9 5.35, m 15, 22 129.7 5.36, m
12 130 5.36, m 14 130.2d 5.35, m 16, 21 129.7 5.36, m
13 27.1 2.02, m 15 27.1 2.03, m 17, 20 27.1 2.03, m
14 29.4 1.36, m 16 29.5 1.36, m 18, 19 29.4 1.36, m
15 29.4 1.36, m 17 29.5 1.36, m
16 27.1 2.02, m 18 27.1 2.03, m
17 130 5.36, m 19 130.1d 5.35, m
18 130 5.36, m 20 129.9 5.35, m
19 27.1 2.02, m 21 27.1 2.03, m
20 29.4 1.36, m 22 29.5 1.36, m
21-25 29.1-29.4 1.28-1.33 23-27 29.3-29.9 1.28-1.32
26 28.7 1.40, m 28 29 1.40, m
27 31.9 2.07, m 29 32.1 2.07, m
28 134.5 5.92, dt (15.1, 6.9) 30 134.7 5.92, dt (15.1, 6.9)
29 128.4 5.61, dd (15.1, 6.2) 31 128.6 5.61, dd (15.1, 6.2)
30 62.8 4.84, brd (6.2) 32 62.9 4.84, brd (6.2)
31 83.3 33 83.6
32 73.9 2.57, d (2.1) 34 74.1 2.57, d (2.1)
(-)-duryne C (2-3) (-)-duryne D (2-4) (-)-duryne E (2-5)
a 13
C NMR spectrum was measured at 150 MHz. 
b
Chemical shifts were assigned from the HSQC data.
d
Assignments with the same superscript in the same column may be interchangeable.
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Miyakosyne A (2-7) had the molecular formula of C29H48O2 as assigned by 
HRESIMS. An interesting feature of the 1H NMR spectrum was that a methyl doublet (δ 
0.84, J=6.7 Hz) was integrated for 1.5 H compared to other isolated 1H signals. This 
observation was accounted for by the presence of one methyl group in otherwise 
symmetrical structure. The 1H NMR and HSQC data showed the presence of 
characteristic terminal structure comprised of terminal acetylene, carbinol, and E-olefin, 
in this order, as found in duryne and petrosynol (Table 2-3).8,9 The molecular formula 
and NMR data indicated that the two termini were linked through a saturated linear 
aliphatic chain with one methyl branch. The branched methyl group was shown not to 
be located near the termini by interpretation of HMBC spectrum. The position of the 
methyl branch was investigated by analysis of tandem FABMS data. Because the 
molecule has an identical polar group placed at both ends, it is likely that each end 
comprises the charged site with the same probability. Therefore, we considered the 
tandem FABMS data as a summation of product ion spectra with each end charged. 
When a methyl branch is present, the regularity of the appearance of product ions 
separated by 14 units, corresponding to the C-C bond cleavages in the aliphatic chain, is 
broken by the absence of one peak, resulting in the separation of two adjacent ions by 
28 units.10 In the tandem FABMS of 2-7, such phenomenon was not observed. Instead, 
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significant fluctuation in the intensities of the ion peaks at m/z 199, 213, 227, and 241 
was observed, while the intensity changes of larger or smaller ions (e.g. m/z 171, 185, 
255, and 269) were within statistical errors (Figure 2-3). In the tandem FABMS of 
methyl branched fatty acids, the incidence of cleavage between α-carbon and β-carbon 
of the branching points is twice as that between the neighboring methylene carbons.10 
With this tendency in mind, we can predict the relative intensity of product ions for a 
specific methyl branch (Figure 2-4, Table 2-4). In the spectrum with C-13 methyl 
branch, the ratio of ion peaks at m/z 185, 199, 213, 227, 241, and 255 was expected to 
be 3:1:3:3:1:3, whereas that with C-14 methyl branch in a ratio of 2:3:2:2:3:2 (Table 
2-4), the latter ratio being matched well with the observed value (Figure 2-3). 
Compounds with methyl branch at C-11 and C-12 would give different ratios from the 
observed value (Table 2-4). Therefore, we concluded that 2-7 had C-14 methyl branch. 
Because of the limited precision of the analysis, it is not possible to eliminate the 
possibility of the presence of small amounts of other positional isomers. The absolute 
configurations of the carbinol carbons were determined as R, because the 1H NMR data 
of the terminal portions of the (R)-MTPA esters of 2-7 were superimposable on those of 
the (S)-MTPA ester of petrocortyne A:11 petrocortyne A contains the corresponding 
terminal moiety with the S-configuration. The configuration of the branched methyl 
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group is discussed in secion 2.2. 
 
 
Table 2-3. 1H and 13C NMR data of Miyakosynes A-D (2-7 - 2-10) in CDCl3. 
 
No. δH, mult.
a
δC δH, mult.
a
δC δH, mult.
b
δC δH, mult.
b
δC
1 2.57, d (2.1) 74.2 2.56, d (2.2) 74.1 2.56, d (2.1) 74.0 2.57, d (2.1) 74.0
2 83.5 83.6 83.4 83.4
3 4.84, brd (6.2) 63.0 4.83, brd (6.2) 62.9 4.84, brd (6.2) 62.8 4.84, brd (6.1) 62.9
4 5.61, dd (15.1, 6.2) 128.5 5.61, dd (15.4, 6.2) 128.5 5.61, dd (15.1, 6.2) 128.3 5.62, dd (15.3, 6.1) 128.4
5 5.92, dt (15.1, 6.9) 134.9 5.91, dt (15.4,6.9) 134.7 5.91, dt (15.1, 6.8) 134.5 5.93, dt (15.3, 6.9) 134.7
6 2.07, m 32.2 2.07, m 32.1 2.07, m 31.9 2.07, m 31.9
7 1.39, m 29.0 1.39, m 29.0 1.39, m 29.0 1.40, m 28.9
8-12 1.24 - 1.31 29.3 - 30.2 1.23 - 1.30 29.3 - 30.2 1.23 - 1.30 29.0 - 30.2 1.23 - 1.30 29.0 - 30.2
13 1.08, m 37.3 1.07, m 37.3 1.07, m 37.0 1.08, m 37.1
14 1.36, m 32.9 1.35, m 32.9 1.35, m 32.7 1.35, m 32.8
15 1.08, m 37.3 1.07, m 37.3 1.07, m 37.0 1.08, m 37.1
16-21 1.24 - 1.31 29.3 - 30.2 1.23 - 1.30 29.3 - 30.2 1.23 - 1.30 29.0 - 30.2 1.23 - 1.30 29.0 - 30.2
22 1.39, m 29.0 1.23 - 1.30 29.3 - 30.2 1.23 - 1.30 29.0 - 30.2 1.23 - 1.30 29.0 - 30.2
23 2.07, m 32.2 1.39, m 29.0 1.23 - 1.30 29.0 - 30.2 1.23 - 1.30 29.0 - 30.2
24 5.92, dt (15.1, 6.9) 134.9 2.07, m 32.1 1.39, m 29.0 1.23 - 1.30 29.0 - 30.2
25 5.61, dd (15.1, 6.2) 128.5 5.91, dt (15.4,6.9) 134.7 2.07, m 31.9 1.40, m 28.9
26 4.84, brd (6.2) 63.0 5.61, dd (15.4, 6.2) 128.5 5.91, dt (15.1, 6.8) 134.5 2.07, m 31.9
27 83.5 4.83, brd (6.2) 62.9 5.61, dd (15.1, 6.2) 128.3 5.93, dt (15.3, 6.9) 134.7
28 2.57, d (2.1) 74.2 83.6 4.84, brd (6.2) 62.8 5.62, dd (15.3, 6.1) 128.4
29 2.56, d (2.2) 74.1 83.4 4.84, brd (6.1) 62.9
30 2.56, d (2.1) 74.0 83.4
31 2.57, d (2.1) 74.0
14-Me 0.84, d (6.7) 19.9 0.84, d (6.6) 19.9 0.84, d (6.6) 19.7 0.84, d (6.6) 19.8
a 13
C NMR was measured at 150 MHz. 
 b 13
C NMR chemical shifts were determined by HSQC data.
miyakosyne D (2-10)miyakosyne A (2-7) miyakosyne B (2-8) miyakosyne C (2-9)
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Figure 2-3. Tandem FAB mass spectrum of miyakosyne A (2-7). 
 
 
 
 
 
 
 
 
 
Figure 2-4. Mass numbers of product ions in the tandem FABMS for 2-7 with a methyl 
branch at C-11 (a), C-12 (b), C-13 (c), and C-14 (d). 
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Table 2-4. Predicted relative intensities of ions for methyl branches at C-11 (a), C-12 (b), 
C-13 (c), and C-14 (d) in 2-7. 
 
m/z 157 171 185 199 213 227 241 255 269 283 
a: 
C-11  
+++ + +++ ++ ++ ++ ++ +++ + +++ 
b: 
C-12  
++ +++ + +++ ++ ++ +++ + +++ ++ 
c: 
C-13  
++ ++ +++ + +++ +++ + +++ ++ ++ 
d: 
C-14  
++ ++ ++ +++ ++ ++ +++ ++ ++ ++ 
 
Miyakosynes B-D (2-8 - 2-10) had molecular formulas of C30H50O2, C31H52O2, 
and C32H54O2, respectively, as assigned by HRESIMS. 
1H and 13C NMR data of 8-10 
were almost identical with those for 2-7, indicating that 2-8 - 2-10 have the common 
terminal structures and a methyl branch (Table 2-3). This was confirmed by analyses of 
2D NMR data. The positions of the methyl branch in 2-8 - 2-10 were all assigned to be 
at C-14 by application of similar arguments on interpretation of tandem FABMS data as 
described above. The absolute configurations of the carbinol carbons in all these 
compounds were determined as R by interpretation of the 1H NMR spectra of the 
bis-(R)-MTPA esters as described above. 
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Table 2-5. 1H and 13C NMR data of Miyakosynes E (2-11) and F (2-12) in CDCl3. 
 
 
 
Miyakosynes E (2-11) and F (2-12), obtained as an inseparable mixture, were 
both isomeric with 2-9. 1H NMR spectrum of the mixture showed one set of resonances 
for the common terminal structure and its rearranged form comprised of an conjugated 
enyne system linked to an allylic secondary alcohol, with a Z-olefin (JH27,H26=11.0 Hz, 
Table 2-5). There was a branched methyl group in this molecule as well. The mixture of 
2-11 and 2-12 gave the tandem FABMS spectrum almost identical with that of 2-9, 
allowing us to locate the methyl group in the aliphatic chain, but it was not possible to 
No. δH, mult.
a δC
1 2.57, d (2.1) 74.0
2 83.3
3 4.84, brd (6.2) 62.8
4 5.62, dd (15.1, 6.2) 128.3
5 5.92, dt (15.1, 6.9) 134.7
6 2.07, m 31.9
7 1.40, m 28.7
8-12 (8-15)b 1.23 - 1.30 29.0 - 30.2
13 (16)
b
1.08, m 37.0
14 (17)
b
1.35, m 32.7
15 (18)b 1.08, m 37.0
16-24 (16-19)b 1.23 - 1.30 29.0 - 30.2
25α 1.63, m 36.5
25β 1.53, m
26 4.68, m 70.0
27 6.00, dd (11.0, 8.3) 147.5
28 5.54, dd (11.0, 1.4) 108.8
29 82.7
30 3.14, d (1.4) 79.4
14-Me (17-Me) 0.84, d (6.6) 19.7
miyakosynes E (2-11) and F (2-12)
a 13
C NMR chemical shifts were determined by HSQC data.
 
b
Parenthetic carbon numbers were assigned for 2-11.
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differentiate the two terminal polar groups which had identical compositions. 
Fortunately, the reactivity of the two secondary alcohols was different: allylic 
propargylic alcohol was much more susceptible to oxidation. DDQ oxidation of the 
mixture afforded a mixture of keto-alcohols (2-13 and 2-14), which was derivatized 
with Girard’s T reagent12 and subjected to the tandem FABMS analysis. In the Girard’s 
T derivatives, the newly introduced positive charge was considered as the sole 
ionization site. The fixed charged site allowed the tandem FABMS data to be interpreted 
unambiguously. We expected the disruption of the regularity of fragments of 14 mass 
units differences by the presence of a branched methyl. Such a disruption was not 
observed.  Instead, intensities of ions at m/z 318 and 360 were weaker than their 
neighboring ions, implying that 2-11 and 2-12 were a mixture of two compounds with a 
branched methyl group at either C-14 or C-17 (Figure 2-5). The absolute configurations 
of 2-11 and 2-12 were both determined to be (3R, 26S) by the modified Mosher’s 
method (Figure 2-6). 
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Figure 2-5. Diagnostic tandem FABMS fragment ions for the Girard’s T derivatives of a 
mixture of 2-13 and 2-14. 
 
 
 
 
Figure 2-6. Result of the modified Mosher’s method for the MTPA ester of 2-11 (m=7, 
n=10) and 2-12 (m=10, n=7). Δδ (δS-δR) values are shown. 
 
(-)-Duryne (2-1) and (-)-durynes B-F (2-2 - 2-6) showed cytotoxic activity 
against HeLa cells with IC50 values of 0.50, 0.26, 0.26, 0.10, 0.08, and 0.34 μM, 
respectively. They are equipotent to duryne, whose reported IC50 values are 0.16-0.23 
μM against P388, HCT-8, A549, and MCF7 cell lines.3 Miyakosynes A-D (2-7 - 2-10) 
and a mixture of miyakosynes E (2-11) and F (2-12) exhibited cytotoxic activity against 
30 
 
HeLa cells with IC50 values of 0.23, 0.29, 0.88, 0.30, and 0.66 μM, respectively. The 
configuration of the allylic propargylic alcohol is variable among acetylenes from 
Petrosia. Only the S-isomers were reported for the petrosynols,13, 14 
adociacetylenes,15duryne,3 petroformynes,16 neopetroformynes,17 petrocortynes,18, 19 and 
the petroformynic acids.20 They invariably exhibit a positive sign of optical rotation. 
However, the R-configuration was assigned for the corresponding carbinol carbons in 
the triangulynes, all of which showed a negative sign of optical rotation.21 Curiously 
scalemic C30-acetylenes were isolated from a Korean Petrosia sp.
22, 23 It is interesting to 
note that (-)-duryne was equipotent to its enantiomer, suggesting that the cellular targets 
of these metabolites do not recognize the configuration of the two secondary alcohols. 
Furthermore, miyakosynes were also equipotent to (-)-durynes, therefore, we reason that 
neither methyl branch nor the central olefin is indispensable for the potent cytotoxicity 
of this class of metabolites. 
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2.1.3. Experimental Section 
 
2.1.3.1. General Experimental Procedures. 
 Optical rotations were measured on a JASCO DIP-1000 digital polarimeter. UV 
spectra were measured on a Shimadzu Biospec 1600. IR spectra were measured with a 
JASCO FT-IR-230 spectrophotometer. NMR spectra were recorded on a JEOL alpha 
600 NMR spectrometer at 300 K. Chemical shifts were referenced to solvent peaks: 
δH7.27 and δc 77.2 for CDCl3. ESI mass spectra were measured on a JEOL 
JMS-T100LC. FABMS and FABMSMS were measured on a JEOL JMS-700T. HPLC 
was carried out on the Shimadzu LC 20AT with a SCL-10Avp controller and a 
SPD-10Avp detector. 
 
2.1.3.2. Animal Material. 
The sponge Petrosia sp. was collected at Miyako sea-knoll, southwestern Japan, 
25º25.64′N, 125º42.48′E, at a depth of 415 m, during a cruise of R/V Natsushima, by 
using the Remotely Operated Vehicle ‘Hyper-Dolphin’ in October 2009.A subglobular 
sponge with an optically smooth surface. A single large oscule with a peripheral sleeve 
opened on top of the body. Color beige. Consistency hard and crumbly. The ectosomal 
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skeleton is different from the choanosomal skeleton, consisting of a tangential 
unispicular network. The choanosomal skeleton consists of an isotropic network. 
Megascleresstrongyles in two size classes, with few oxeas. Microscleresabsent. The 
comparable species are P. spheroida Tanita, 1967 and P. solusstrongyla Hoshino, 1981 
based on its external morphology. P. spheroida is distinguished from the present species 
by its bean-shaped microstrongyles. P. solusstrongyla has strongyles only, and the form 
and size of strongyles are variable. Habitat of the present species is also different from 
the two species. P. spheroida is reported from the shallow water of southwestern region 
of Japan Sea and P. solusstrongylais reported from the subtidal zone to a depth of 15 m 
in Kagoshima. The specimen used for the identification (NSMT-Po1954) was deposited 
at National Museum of Nature and Science, Tokyo. 
 
2.1.3.3. Extraction and Isolation. 
 The sponge was frozen after collection and kept frozen until extraction. The sponge 
(130 g, wet weight) was homogenized and extracted with EtOH (350 mL x 3) and 
CHCl3/MeOH (1:1) (350 mL). The combined extracts were concentrated, and 
partitioned between H2O (200 mL) and CHCl3 (200 mL x 3). The CHCl3 layer (IC50 
value against HeLa cells 0.4 μg/mL) was further partitioned between n-hexane (100 
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mL) and 90% MeOH (100 mL). The 90% MeOH layer (IC50 0.4 μg/mL) was 
concentrated and subjected to ODS column chromatography eluting with 50 % MeOH, 
70 % MeOH (IC50 10 μg/mL), 90% MeOH (IC50 10 μg/mL), MeOH (IC50 0.4 μg/mL), 
and CHCl3/MeOH/H2O (6:4:1, IC50 22 μg/mL). The MeOH eluate was concentrated and 
subjected to silica gel column chromatography eluting with CHCl3 (IC50 0.4 μg/mL), 
CHCl3/MeOH (98:2, IC50 4.5 μg/mL), CHCl3/MeOH (95:5, IC50 4.5 μg/mL), 
CHCl3/MeOH (9:1), CHCl3/MeOH/H2O (8:2:0.1), and CHCl3/MeOH/H2O (7:3:0.5). 
The CHCl3 eluate was subjected to silica gel column chromatography eluting with 
n-hexane/EtOAc (9:1, IC50 4.5 μg/mL), n-hexane/EtOAc (8:2, IC50 0.4 μg/mL), and 
n-hexane/EtOAc (1:1, IC50 4.5 μg/mL). The n-hexane/EtOAc (8:2) eluate was 
concentrated and separated by ODS HPLC (Cosmosil AR-II; 10 x 250 mm) with 90% - 
100% MeOH to afford 14 fractions. The second fraction was purified by ODS HPLC 
(Cosmosil MS-II; 10 x 250 mm) with 85% MeCN to afford 2-1 (6.3 mg), 2-7 (21.6 mg), 
2-9 (37 mg). The third fraction was purified by ODS HPLC with 86% MeCN to afford 
2-3 (2.0 mg). The fifth fraction was purified by ODS HPLC with 90% MeCN to afford 
2-8 (66 mg). The sixth fraction was purified by ODS HPLC with 90% MeCN to afford 
2-6 (1.8 mg). The seventh fraction was purified by ODS HPLC with 85% MeCN to 
afford 2-2 (15.6 mg), 2-11 and 2-12 (7.2 mg). The eighth fraction was purified by ODS 
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HPLC with 90% MeCN to afford 2-4 (16.0 mg). The ninth fraction was purified by 
ODS HPLC with 90% MeCN to afford 2-10 (8.6 mg). The thirteenth fraction was 
purified by ODS HPLC with 93% MeCN to afford 2-5 (1.2 mg). 
2.1.3.3.1. (-)-duryne (2-1): white solids; [α]17D -19 (c 0.27, CHCl3); IR (film) νmax 
3400-3360 (br), 3282, 2917, 2852, 2118, 1654, 1467, 1088, 962 cm-1;1H NMR data 
(CDCl3), see Table 1; 
13C NMR data (CDCl3), see Table 1; HRESIMS m/z 463.3524 
[M+Na]+ (calcd for C30H48O2Na, 463.3552) 
2.1.3.3.2. (-)-duryne B (2-2): white solids; [α]26D -17 (c 0.34, CHCl3); UV (MeOH) 
λmax(log ε) 206 (3.57); IR (film) νmax 3440-3400 (br), 2916, 2849, 2121, 1647, 1468, 
1215 cm-1; 1H NMR data (CDCl3), see Table 1; 
13C NMR data (CDCl3), see Table 1; 
HRESIMS m/z 491.3857 [M+Na]+ (calcd for C32H52O2Na, 491.3865) 
2.1.3.3.3. (-)-duryne C (2-3): white solids; [α]25D -61 (c 0.05, CHCl3); UV (MeOH) 
λmax(log ε) 207 (3.60); IR (film) νmax 3400-3360 (br), 3307, 3005, 2925, 2853, 2118, 
1655, 1459, 1012, 968 cm-1;1H NMR data (CDCl3), see Table 2; 
13C NMR data (CDCl3), 
see Table 2; HRESIMS m/z 489.3706 [M+Na]+ (calcd for C32H50O2Na, 489.3708). 
2.1.3.3.4. (-)-duryne D (2-4): white solids; [α]26D -38 (c 0.22, CHCl3); UV (MeOH) 
λmax(log ε) 206 (3.59); IR (film) νmax 3400-3340 (br), 3290, 2997, 2920, 2849, 2120, 
1654, 1459, 1215, 964 cm-1;1H NMR data (CDCl3), see Table 2; 
13C NMR data (CDCl3), 
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see Table 2; HRESIMS m/z 517.3986 [M+Na]+ (calcd for C34H54O2Na, 517.4021). 
2.1.3.3.5. (-)-duryne E (2-5): white solids; [α]26D -120 (c 0.02, MeOH); UV (MeOH) 
λmax(log ε) 210 (3.73); 1H NMR data (CDCl3), see Table 2; 13C NMR data (CDCl3), see 
Table 2; HRESIMS m/z 545.4351 [M+Na]+ (calcd for C36H58O2Na, 545.4334) 
2.1.3.3.6. (-)-duryne F (2-6): white solids; [α]26D -32 (c 0.04, CHCl3); UV (MeOH) 
λmax(log ε) 225 (3.76); IR (film) νmax 3400-3360 (br), 3308, 2922, 2851, 2120, 1655, 
1459, 1014, 968 cm-1;1H NMR data (CDCl3), see Table 1; 
13C NMR data (CDCl3), see 
Table 1; HRESIMS m/z 491.3846 [M+Na]+ (calcd for C32H52O2Na, 491.3865) 
2.1.3.3.7. miyakosyne A (2-7)  
Colorless solid; [α]D24 -28 (c 0.42, MeOH); HRESIMS (M+Na)+m/z 451.3548 (calcd for 
C29H48O2Na
+, 451.3547); 1H NMR (CDCl3) and 
13C NMR (CDCl3) data, see table 1. 
2.1.3.3.8. miyakosyne B (2-8)  
Colorless solid; [α]D26 -27 (c 0.60, MeOH); HRESIMS (M+Na)+m/z 465.3735 (calcd for 
C30H50O2Na
+, 465.3704); 1H NMR (CDCl3) and 
13C NMR (CDCl3) data, see table 1. 
2.1.3.3.9. miyakosyne C (2-9)  
Colorless solid; [α]D24 -28 (c 0.72, MeOH); HRESIMS (M+Na)+m/z 479.3856 (calcd for 
C31H52O2Na
+, 479.3860); 1H NMR (CDCl3) and 
13C NMR (CDCl3) data, see table 1. 
2.1.3.3.10. miyakosyne D (2-10)  
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Colorless solid; [α]D26 -25 (c 0.35, MeOH); HRESIMS (M+Na)+m/z 493.4036 (calcd for 
C32H54O2Na
+, 493.4017); 1H NMR (CDCl3) and 
13C NMR (CDCl3) data, see table 1. 
2.1.3.3.11. miyakosynes E and F (2-11, 2-12)  
Colorless oil; [α]D25 -34 (c 0.32, MeOH); HRESIMS (M+Na)+m/z 479.3882 (calcd for 
C31H52O2Na
+,479.3860); 1H NMR (CDCl3) and 
13C NMR (CDCl3) data, see Table 3. 
 
2.1.3.4. Preparation of MTPA Esters. 
 To solutions of samples 2-1 - 2-12 (0.1 mg each) in dry pyridine (10 μL) was added 
(S)-MTPACl (2 μL). The solutions were left at room temperature for 4 h-15 h, and the 
reaction mixtures were diluted with H2O and extracted with CHCl3. The organic layers 
were purified by reversed-phase HPLC to afford the (R)-MTPA esters. (S)-MTPA esters 
of 2-1 - 2-6, 2-11 - 2-12 were prepared in a similar way using (R)-MTPACl. 
2.1.3.4.1. (R)-MTPA Ester of 2-1 (2-1a):1H NMR (CDCl3) δ 6.04 (H-3, H-28), 6.02 
(H-5, H-26), 5.50 (H-4, H-27), 5.35 (H-15, H-16), 2.64 (H-1, H-30), 2.05 (H-6, H-25), 
2.02 (H-14, H-17), 1.26 - 1.36 (H-7 - H-13, H-18 - H-24): ESIMS m/z 895 [M+Na]+ 
2.1.3.4.2. (S)-MTPA Ester of 2-1 (2-1b):1H NMR (CDCl3) δ6.08 (H-5, H-26), 6.02 
(H-3, H-28), 5.61 (H-4, H-27), 5.35 (H-15, H-16), 2.60 (H-1, H-30), 2.09 (H-6, H-25), 
2.02 (H-14, H-17), 1.27 - 1.39 (H-7 - H-13, H-18 -H-24): ESIMS m/z 895 [M+Na]+ 
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2.1.3.4.3. (R)-MTPA Ester of 2-2 (2-2a):1H NMR (CDCl3) δ 6.04 (H-3, H-30), 6.02 
(H-5, H-28), 5.50 (H-4, H-29), 5.35 (H-15, H-16), 2.64 (H-1, H-32), 2.05 (H-6, H-27), 
2.02 (H-14, H-17), 1.26 - 1.37 (H-7 -H-13, H-18 - H-26); ESIMS m/z 923 [M+Na]+ 
2.1.3.4.4. (S)-MTPA Ester of 2-2 (2-2b): 1H NMR (CDCl3) δ 6.08 (H-5, H-28), 6.02 
(H-3, H-30), 5.61 (H-4, H-29), 5.35 (H-15, H-16), 2.60 (H-1, H-32), 2.09 (H-6, H-27), 
2.02 (H-14, H-17), 1.27 - 1.40 (H-7 - H-13, H-18 -H-26); ESIMS m/z 923 [M+Na]+ 
2.1.3.4.5. (R)-MTPA Ester of 2-3 (2-3a):1H NMR (CDCl3) δ 6.04 (H-3, H-30), 6.02 
(H-5, H-28), 5.50 (H-4, H-29), 5.35 (H-11, H-12, H-17, H-18), 2.64 (H-1, H-32), 2.05 
(H-6, H-27), 2.02 (H-10, H-13, H-16, H-19), 1.27 - 1.38 (H-7 - H-9, H-14 - H-15, H-20 
- H-26); ESIMS m/z 921 [M+Na]+ 
2.1.3.4.6. (S)-MTPA Ester of 2-3 (2-3b):1H NMR (CDCl3) δ 6.08 (H-5, H-28), 6.02 
(H-3, H-30), 5.61 (H-4, H-29), 5.35 (H-11, H-12, H-17, H-18), 2.60 (H-1, H-32), 2.09 
(H-6, H-27), 2.02 (H-10, H-13, H-16, H-19), 1.27 - 1.40 (H-7 - H-9, H-14 - H-15, H-20 
- H-26); ESIMS m/z 921 [M+Na]+ 
2.1.3.4.7. (R)-MTPA Ester of 2-4 (2-4a):1H NMR (CDCl3) δ 6.04 (H-3, H-32), 6.02 
(H-5, H-30), 5.50 (H-4, H-31), 5.35 (H-13, H-14, H-19, H-20), 2.64 (H-1, H-34), 2.05 
(H-6, H-29), 2.02 (H-12, H-15, H-18, H-21), 1.26 - 1.36 (H-7 - H-11, H-16 - H-17, 
H-22 - H-28); ESIMS m/z 949 [M+Na]+ 
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2.1.3.4.8. (S)-MTPA Ester of 2-4 (2-4b): 1H NMR (CDCl3) δ 6.08 (H-5, H-30), 6.02 
(H-3, H-32), 5.61 (H-4, H-31), 5.35 (H-13, H-14, H-19, H-20), 2.60 (H-1, H-34), 2.09 
(H-6, H-29), 2.02 (H-12, H-15, H-18, H-21), 1.26 - 1.39 (H-7 - H-11, H-16 - H-17, 
H-22 - H-28); ESIMS m/z 949 [M+Na]+ 
2.1.3.4.9. (R)-MTPA Ester of 2-5 (2-5a):1H NMR (CDCl3) δ 6.04 (H-3, H-34), 6.02 
(H-5, H-32), 5.50 (H-4, H-33), 5.35 (H-15, H-16, H-21, H-22), 2.64 (H-1, H-36), 2.05 
(H-6, H-31), 2.02 (H-14, H-17, H-20, H-23), 1.26 - 1.37 (H-7 - H-13, H-18 - H-19, 
H-24 - H-30); ESIMS m/z 977 [M+Na]+ 
2.1.3.4.10. (S)-MTPA Ester of 2-5 (2-5b):1H NMR (CDCl3) δ 6.08 (H-5, H-32), 6.02 
(H-3, H-34), 5.61 (H-4, H-33), 5.35 (H-15, H-16, H-21, H-22), 2.60 (H-1, H-36), 2.09 
(H-6, H-31), 2.02 (H-14, H-17, H-20, H-23), 1.27 - 1.41 (H-7 - H-13, H-18 - H-19, 
H-24 - H-30) ESIMS m/z 977 [M+Na]+ 
2.1.3.4.11. (R)-MTPA Ester of 2-6 (2-6a):1H NMR (CDCl3) δ 6.04 (H-3), 6.02 (H-5), 
5.95 (H-28), 5.83 (H-29), 5.64 (H-30), 5.36 (H-15, H-16), 5.50 (H-4), 3.25 (H-32), 2.64 
(H-1), 2.05 (H-6), 2.02 (H-14, H-17), 1.81 (H-27α), 1.68 (H-27β), 1.26 - 1.36 (H-7 - 
H-13, H-18 - H-26); ESIMS m/z 923 [M+Na]+ 
2.1.3.4.12. (S)-MTPA Ester of 2-6 (2-6b):1H NMR (CDCl3) δ 6.08 (H-5), 6.02 (H-3), 
6.00 (H-29), 5.96 (H-28), 5.67 (H-30), 5.61 (H-4), 5.36 (H-15, H-16), 3.26 (H-32), 2.60 
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(H-1), 2.09 (H-6), 2.02 (H-14, H-17), 1.74 (H-27α), 1.23 - 1.61 (H-7 - H-13, H-18 - 
H-26, H-27β); ESIMS m/z 923 [M+Na]+ 
2.1.3.4.13. (R)-MTPA ester of 2-7: 1H NMR (CDCl3) δ 6.04 (H-3, H-26), 6.02 (H-5, 
H-24), 5.50 (H-4, H-25), 2.64 (H-1, H-28), 2.05 (H-6, H-23), 1.24-1.64 (H-7 - H-12, 
H-16 - H-22), 1.36 (H-14), 1.08 (H-13, H-15), 0.84 (14-Me); ESIMS m/z 899 (M+Na)+ 
2.1.3.4.14. (R)-MTPA ester of 2-8: 1H NMR (CDCl3) δ 6.04 (H-3, H-27), 6.02 (H-5, 
H-25), 5.50 (H-4, H-26), 2.64 (H-1, H-29), 2.05 (H-6, H-24), 1.24-1.64 (H-7 - H-12, 
H-16 - H-23), 1.35 (H-14), 1.08 (H-13, H-15), 0.84 (14-Me); ESIMS m/z 913 (M+Na)+ 
2.1.3.4.15. (R)-MTPA ester of 2-9: 1H NMR (CDCl3) δ 6.04 (H-3, H-28), 6.02 (H-5, 
H-26), 5.50 (H-4, H-27), 2.64 (H-1, H-30), 2.05 (H-6, H-25), 1.24-1.64 (H-7 - H-12, 
H-16 - H-24), 1.35 (H-14), 1.08 (H-13, H-15), 0.84 (14-Me); ESIMS m/z 927 (M+Na)+ 
2.1.3.4.16. (R)-MTPA ester of 2-10: 1H NMR (CDCl3) δ 6.04 (H-3, H-29), 6.02 (H-5, 
H-27), 5.50 (H-4, H-28), 2.64 (H-1, H-31), 2.05 (H-6, H-26), 1.24-1.64 (H-7 - H-12, 
H-16 - H-25), 1.35 (H-14), 1.08 (H-13, H-15), 0.84 (14-Me); ESIMS m/z 941 (M+Na)+ 
2.1.3.4.17. (R)-MTPA ester of 2-11 and 2-12: 1H NMR for (R)-MTPA ester of 5 and 6 
(CDCl3) δ 6.04 (H-3), 6.02 (H-5), 5.95 (H-26), 5.83 (H-27), 5.64 (H-28), 5.50 (H-4), 
3.26 (H-30), 2.64 (H-1), 2.05 (H-6), 1.81 (H-25α): (R)-MTPA ester of 11 1.25-1.68 (H-7 
- H-12, H-16 - H-24, H-25β), 1.35 (H-14), 1.08 (H-13, H-15), 0.84 (14-Me); (R)-MTPA 
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ester of 12 1.25-1.68 (H-7 - H-15, H-19 - H-24, H-25β), 1.35 (H-17), 1.08 (H-16, H-18), 
0.84 (17-Me); ESIMS m/z 911 (M+Na)+ 
2.1.3.4.18. (S)-MTPA ester of 2-11 and 2-12: 1H NMR for (S)-MTPA ester of 11 and 
12 (CDCl3) δ 6.08 (H-5), 6.02 (H-3), 6.00 (H-27), 5.97 (H-26), 5.67 (H-28), 5.61 (H-4), 
3.27 (H-30), 2.60 (H-1), 2.05 (H-6), 1.74 (H-25α): (S)-MTPA ester of 5 1.23-1.63 (H-7 - 
H-12, H-16 - H-24, H-25β), 1.36 (H-14), 1.08 (H-13, H-15), 0.84 (14-Me); (S)-MTPA 
ester of 6 1.23-1.63 (H-7 - H-15, H-19 - H-24, H-25β), 1.36 (H-17), 1.08 (H-16, H-18), 
0.84 (17-Me); ESIMS m/z 911 (M+Na)+ 
 
2.1.3.5. Ozonolysis of 2-2 - 2-6. Separately solution of acetylenes, 2-2 - 2-6 (0.5 mg 
each) in CH2Cl2 (1 mL) were treated with O3 at -78ºC for 15 min. After excess O3 was 
removed by a stream of N2, the reaction mixtures were treated with 90% HCOOH/35% 
H2O2 (2:1, 1 mL) at room temperature for 15 min. The products were concentrated and 
subjected to FABMS without further separation. 
 
2.1.3.6. keto-alcohols 2-13 and 2-14 
To a mixture of 2-11 and 2-12 (0.5 mg) was added DDQ solution in dioxane (15 mg/mL, 
20 μL). The solution was left at room temperature for a week, and the reaction mixture 
41 
 
was purified by silica gel column chromatography eluted with n-hexane/EtOAc (95:5) 
to afford a mixture of keto-alcohols 2-13 and 2-14(0.2 mg) 
2.1.3.6.1. keto-alcohols 2-13 and 2-14 
Colorless oil; HRESIMS (M+Na)+ m/z 477.3698 (calcd for C31H50O2Na
+, 477.3704); 1H 
NMR of keto-alcohol 2-13 and 2-14 (CDCl3) δ 7.26 (m, H-5), 6.19 (d, J=15.6, H-4), 
6.00 (dd, J=11.0, 8.3, H-27), 5.54 (dd, J=11.0, 1.4, H-28), 4.68 (m, H-26), 3.22 (s, H-1), 
3.14 (d, J=1.4, H-30), 2.32 (m, H-6), 1.63 (m, H-25α), 1.53 (m, H-25β): 2-13 1.35 (m, 
H-14), 1.08 - 1.40 (H-7 - H-13, H-15 - H-24), 0.84 (d, J=6.6, 14-Me); 2-141.35 (m, 
H-17), 1.08 - 1.40 (H-7 - H-16, H-18 - H-24), 0.84 (d, J=6.6, 17-Me) 
 
2.1.3.7. Preparation of Girard’s T derivatives of 2-13 and 2-14. 
To a portion of a mixture of 2-13 and 2-14 (0.1 mg) was added Girard’s reagent T in 
AcOH (50 mg/mL, 20 μL) and the solution was kept at 70 ºC for 30 min. The reaction 
mixture was evaporated by a stream of dry nitrogen and diluted with MeOH (5 μL) 
before application to tandem FABMS analysis. 
 
2.1.3.8. Cytotoxicity Assay. 
The cytotoxicities of 2-1 - 2-12 against HeLa cells were evaluated by an MTT assay.24 
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HeLa human cervical cancer cells were cultured in Dulbecco’s modified Eagle’s 
medium containing 10% fetal bovine serum, 2 μg/mL gentamycin, and 2 μg/mL 
antibiotic-antimicotic (Gibco) at 37°C under an atomosphere of 5% CO2. To each well 
of a 96-well microplate containing 200 μL of tumor cell suspension (1 x 104 cells/mL) 
was added a sample after 24 h preincubation, and the plate was incubated for 72 h. After 
addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) saline 
solution (1 mg/mL, 50 μL) to each well, the plate was incubated for 3 h. After the 
incubation, the supernatant was discarded and DMSO (150 μL) was added. The 
absorbance was measured to determine IC50 values. In this assay, adriamycin was used 
as a positive control (IC50 1.64 μM). 
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Figure S2-1-1. 1H NMR spectrum of (-)-duryne (2-1) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-2. 13C NMR spectrum of (-)-duryne (2-1) in CDCl3 
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Figure S2-1-3. 1H NMR spectrum of (-)-duryne B (2-2) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-4. COSY spectrum of (-)-duryne B (2-2) in CDCl3 
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Figure S2-1-5. HSQC spectrum of (-)-duryne B (2-2) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-6. HMBC spectrum of (-)-duryne B (2-2) in CDCl3  
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Figure S2-1-7. 1H NMR spectrum of (-)-duryne C (2-3) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-8. COSY spectrum of (-)-duryne C (2-3) in CDCl3 
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Figure S2-1-9. HSQC spectrum of (-)-duryne C (2-3) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-10. HMBC spectrum of (-)-duryne C (2-3) in CDCl3 
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Figure S2-1-11. 1H NMR spectrum of (-)-duryne D (2-4) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-12. 13C NMR spectrum of (-)-duryne D (2-4) in CDCl3  
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Figure S2-1-13. COSY spectrum of (-)-duryne D (2-4) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-14. HSQC spectrum of (-)-duryne D (2-4) in CDCl3 
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Figure S2-1-15. HMBC spectrum of (-)-duryne D (2-4) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-16. 1H NMR spectrum of (-)-duryne E (2-5) in CDCl3 
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Figure S2-1-17. COSY spectrum of (-)-duryne E (2-5) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-18. HSQC spectrum of (-)-duryne E (2-5) in CDCl3 
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Figure S2-1-19. HMBC spectrum of (-)-duryne E (2-5) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-20. 1H NMR spectrum of (-)-duryne F (2-6) in CDCl3 
 
53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-21. COSY spectrum of (-)-duryne F (2-6) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-22. HSQC spectrum of (-)-duryne F (2-6) in CDCl3 
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Figure S2-1-23. HMBC spectrum of (-)-duryne F (2-6) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-24. FABMSMS spectrum of (-)-duryne (2-1) 
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Figure S2-1-25. FABMSMS spectrum of (-)-duryne B (2-2) 
 
 
Figure S2-1-26. FABMSMS spectrum of (-)-duryne C (2-3) 
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Figure S2-1-27. FABMSMS spectrum of (-)-duryne D (2-4) 
 
 
 
Figure S2-1-28. FABMSMS spectrum of (-)-duryne E (2-5) 
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Figure S2-1-29. FABMSMS spectrum of (-)-duryne F (2-6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 R=(R)-MTPAor(S)-MTPA 
 
Figure S2-1-30. Result of the modified Mosher’s method. Δδ (δS-δR) values for the 
MTPA esters of 2-2 - 2-6. 
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Figure S2-1-31. 1H NMR spectrum of miyakosyne A (2-7) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-32. 13C NMR spectrum of miyakosyne A (2-7) 
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Figure S2-1-33. COSY spectrum of miyakosyne A (2-7) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-34. HSQC spectrum of miyakosyne A (2-7) in CDCl3 
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Figure S2-1-35. HMBC spectrum of miyakosyne A (2-7) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-36. 1H NMR spectrum of miyakosyne B (2-8) in CDCl3 
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Figure SS2-1-37. 13C NMR spectrum of miyakosyne B (2-8) in CDCl3 
 
 
 
Figure S2-1-38. COSY spectrum of miyakosyne B (2-8) in CDCl3 
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Figure S2-1-39. HSQC spectrum of miyakosyne B (2-8) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-40. HMBC spectrum of miyakosyne B (2-8) in CDCl3 
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Figure S2-1-41. 1H NMR spectrum of miyakosyne C (2-9) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-42. COSY spectrum of miyakosyne C (2-9) in CDCl3 
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Figure S2-1-43. HSQC spectrum of miyakosyne C (2-9) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-44. HMBC spectrum of miyakosyne C (2-9) in CDCl3 
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Figure S2-1-45. 1H NMR spectrum of miyakosyne D (2-10) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-46. COSY spectrum of miyakosyne D (2-10) in CDCl3 
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Figure S2-1-47. HSQC spectrum of miyakosyne D (2-10) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-48. HMBC spectrum of miyakosyne D (2-10) in CDCl3 
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Figure S2-1-49. 1H NMR spectrum of miyakosynes E (2-11) and F (2-12) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-50. COSY spectrum of miyakosynes E (2-11) and F (2-12) in CDCl3 
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Figure S2-1-51. HSQC spectrum of miyakosynes E (2-11) and F (2-12) in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2-1-52. HMBC spectrum of miyakosynes E (2-11) and F (2-12) in CDCl3 
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Figure S2-1-53. 1H NMR spectrum of keto-alcohols (2-13) and (2-14) in CDCl3 
 
 
Figure S2-1-54. Tandem FABMS spectrum of miyakosyne A (2-7) 
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Figure S2-1-55. Tandem FABMS spectrum of miyakosyne B (2-8) 
 
 
Figure S2-1-56. Tandem FABMS spectrum of miyakosyne C (2-9) 
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Figure S2-1-57. Tandem FABMS spectrum of miyakosyne D (2-10) 
 
 
 
Figure S2-1-58. Tandem FABMS spectrum of miyakosynes E (2-11) and F (2-12) 
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Figure S2-1-59. Tandem FABMS spectrum of Girard’s T derivative  
 
 
 
Figure S2-1-60. Photograph of the sponge Petrosia sp. 
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2.2. Assignment of the absolute configuration at the isolated methyl branch in 
miyakosyne A 
 
 
 
2.2.1. Introduction 
Enantiomer or diastereomers of bioactive compounds often exhibit different 
biological activity.25 Therefore, assignment of the absolute configuration of chiral 
centers in small molecules is the essential part for the structure elucidation of bioactive 
natural products. Recent improvements of the analytical techniques of NMR, including 
modified Mosher’s method,5 universal NMR database,26 and J-based configurational 
analysis,27 enabled us to analyze complicated configuration of natural products. 
However, determination of the absolute configuration of chiral centers in the molecules 
consisting of symmetrical partial structures is problematic, because overlapped NMR 
signals hamper the assignment of the each signal. Additionally, the chiral discrimination 
of a branched methyl located at the remote position is also challenging subjects as 
well.28, 29 
Miyakosyne A (2-7) has the common substructures at both termini, and a 
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branched methyl in the middle of a long methylene chain, thus assignment of the 
absolute configuration of the methyl branch was difficult.30 Innovative X-ray 
crystallographic analysis using porous complex was applied for the structure elucidation 
of miyakosyne A, and the absolute configuration of the isolated chiral center was 
tentatively assigned as 14S.31, 32 In this study, we assigned the absolute configuration of 
the isolated chiral center of miyakosyne A by chemical degradation and esterification 
with the Akasaka-Ohrui’s reagent (2-15, Figure 2-7).33 
 
 
 
 
 
 
 
Figure 2-7. Structures of miyakosyne A (2-7) and 
(1S,2S)-2-(anthracene-2,3-dicarboximido)cyclohexanecarboxylic acid (2-15). 
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2.2.2. Results and Discussion 
We first attempted to examine whether miyakosyne A (2-7) is a diastereomeric 
mixture differing in the configuration at C-14 or not. In order to obtain diastereomers of 
2-7, we randomized the configurations of two secondary alcohols by a sequence of 
oxidation and reduction reactions. Even though the modified Mosher’s analysis of the 
product demonstrated that the two oxygenated methines were racemic, the mixture gave 
only a single sharp peak in a variety of HPLC conditions.34 
Then we set out to convert 2-7 into a linear 1,-diol. It was reported that a pair 
of isomers of linear primary alcohols with anteiso-terminus, which are enantiomeric to 
each other in the absolute configuration of the methyl-substituted methine carbons, 
could be discernible by 1H NMR spectroscopy by conjugation with the Ohrui’s acid 
(2-15) (Ohrui’s method).33 It was also reported that the differences in chemical shifts 
between the enantiomers were not observed when the branching points were more 
distant than the 10th carbon atom.33 With this information in mind, miyakosyne A (2-7) 
was subjected to ozonolysis followed by reduction with NaBH4 to furnish 
10-methylicosane-1,20-diol (2-16). In compound 2-16 the branched methyl group was 
placed at 10th and 11th carbon from each terminus, which were too far to apply the 
Ohrui’s method. Therefore, compound 2-16 was dehomologated by means of the Grieco 
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elimination35 followed by ozonolysis and reduction with NaBH4 to give 
9-methyl-1,18-octadecanediol (2-18), in which branched methyl group was placed at 9th 
and 10th position (Scheme 2-2).  
 
 
Scheme 2-2. Preparation of 9-methyl-1,18-octadecanediol (2-18) from miyakosyne A 
 
 
 
 
 
 
 
We then prepared both enantiomers of 9-methyl-1,18-octadecanediol. 
(S)-Citronellal (S-2-19) was subjected to ozonolysis to afford S-2-20. S-2-20 was treated 
with the ylide prepared from phosphonium salt 2-21 to give S-2-22, which was 
hydrogenated to give S-2-18 (Scheme 2-3). R-2-18 was synthesized in the same way 
from R-citronellal (R-2-19).  
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Scheme 2-3. Synthesis of (S)-9-methyl-1,18-octadecanediol (S-2-18). 
 
 
 
With 2-18 from 2-7 and both enantiomers of 2-18 in hand, we esterified each of 
them with 2-15. The 1H NMR spectra of the resulting three diesters appeared identical 
except for the chemical shift of the branched methyl signal (Figure 2-8). The chemical 
shift of the methyl signal in the diester of natural 2-18 was identical with that of the 
diester of R-2-18, whereas it shifted down-field compared to that of the diester of S-2-18. 
From this result we considered that miyakosyne A has 14R-configuration. 
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Figure 2-8. Expanded plots of the1H NMR spectrum of the terminal oxygenated 
methylene protons (Left) and the branched methyl (Right) signals of the diesters. (a) 
S-2-18, (b) R-2-18, and (c) 2-18 prepared from miyakosyne A (2-7). 
 
2.2.3. Conclusion 
The absolute configuration of the methyl branch in miyakosyne A (2-7) has 
been determined to be 14R by comparing the 1H NMR data of a degradation product 
with those of synthetic standards after derivatization with the Ohrui’s acid. This study 
demonstrates the efficiency of derivatization with the Ohrui’s acid to assign the absolute 
configuration of remote stereogenic centers once reference compounds are available.28 
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The differentiation of a methyl branch 9 and 10 carbons away from the terminal 
hydroxyl groups was fulfilled by 1H NMR, permitting us to conclude that the natural 
miyakosyne A has the 3R, 14R, 26R-configuration. 
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2.2.4．Experimental Section 
 
2.2.4.1. General Experimental Procedures 
1H and 13C NMR spectra were recorded on a JEOL alpha 600 NMR spectrometer. 
Chemical shifts were referenced to solvent peaks: δH 7.24 and δC 77.0 for CDCl3. High 
resolution mass spectra were obtained on a JEOL JMS-700T mass spectrometer. Optical 
rotations were measured on a JASCO DIP-1000 digital polarimeter. 
 
2.2.4.2. 10-Methyl-1,20-icosanediol (2-16) 
O3 was bubbled through a solution of miyakosyne A (2-7, 3.5 mg) in MeOH (2.5 mL) at 
-78 °C until the color of the solution changed to blue. After excess O3 was purged with 
N2, NaBH4 was added and stirred for 1 h. To the reaction mixture water was added and 
the solution was extracted with EtOAc to afford 10-methyl-1,20-icosanediol (2-16, 2.3 
mg) as a colorless oil: 1H-NMR (600 MHz, CDCl3) δ 0.81 (d, J = 6.9 Hz, 3H), 1.06 (m, 
2H), 1.19–1.33 (m, 28H), 1.52–1.57 (m, 5H), 3.62 (t, J = 6.9 Hz, 4H); HRFABMS calcd 
for C21H45O2 [M+H
+] 329.3414, found: 329.3412. 
 
2.2.4.3. 10-Methyl-1,19-icosadiene (2-17) 
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To a solution of 2-16 (1.5 mg) in THF (0.3 mL) o-NO2PhSeCN (5 mg) and Bu3P (6 μL) 
was added. After stirring for 4 h, the reaction mixture was cooled to 0 °C, and H2O2 (0.2 
mL) in THF (3 mL) was added. The reaction mixture was stirred at 0 °C for 30 min, and 
allowed to warm to room temperature and stirred overnight. The reaction mixture was 
quenched by addition of saturated aqueous NaHCO3, and the mixture was extracted 
with EtOAc. The organic layer was concentrated, and the residue was subjected to silica 
gel column chromatography (n-hexane) to afford 10-methyl-1,19-icosadiene (2-17, 1.5 
mg) as a pale yellow solid: 1H-NMR (600 MHz, CDCl3) δ 0.81 (d, J = 6.9 Hz, 3H), 1.06 
(m, 2H), 1.19–1.35 (m, 24H), 1.56 (m, 1H), 2.01 (m, 4H), 4.91 (brd, J = 9.6 Hz, 2H), 
4.97 (brd, J = 17.1 Hz, 2H), 5.80 (m, 2H). 
 
2.2.4.4. 9-Methyl-1,18-octadecanediol (2-18) 
17 (1.5 mg) was dissolved in CH2Cl2 and O3 was bubbled through the solution until the 
color turned blue. After the excess O3 was purged with N2, MeOH and NaBH4 were 
added and stirred for 1 h at room temperature. The reaction mixture was concentrated 
and partitioned between water and EtOAc. Concentration of the organic layer afforded 
9-methyl-1,18-octadecanediol (2-18, 1.0 mg) as a colorless oil: 1H-NMR (600 MHz, 
CDCl3) δ 0.81 (d, J = 6.9, 3H), 1.05 (m, 2H), 1.23–1.33 (m, 24H), 1.52–1.66 (m, 5H), 
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3.62 (t, J = 6.9, 4H); HRFABMS calcd for C19H41O2 [M+H
+] 301.3101, found: 
301.3100. 
 
2.2.4.5. (S)-3-Methyl-1,6-hexanedial (S-2-20) 
A solution of (S)-(-)-citronellal (S-2-19) (170 mg, 1.1 mmol) in CH2Cl2 (7 mL) was kept 
at -78 °C and bubbled with ozone until the color of the solution turned blue. Me2S (180 
μL) was added to the reaction mixture and gradually warmed to room temperature. The 
reaction mixture was stirred for overnight, and the solvent was removed by evaporation. 
The residue was purified by silica gel column chromatography (n-hexane/ ethyl acetate 
1:1) to afford a fraction enriched with (S)-3-methyl-1,6-hexanedial (S-2-20 110 mg) as a 
colorless oil which was used in the next step: [α]23D -12 (c 0.75, CHCl3); 1H-NMR (600 
MHz, CDCl3) δ 0.95 (m, 3H), 1.47–1.56 (m, 1H), 1.69 (m, 1H), 1.95 (m, 1H), 2.16 (m, 
1H), 2.30–2.44 (m, 3H), 9.71 (brs, 1H), 9.73 (brs, 1H); 13C-NMR (200 MHz, CDCl3) δ 
19.0, 26.8, 28.0, 40.7, 50.0, 202.0, 202.1; HRFABMS calcd for C7H11O2 [M-H
-], 
127.0765, found: 127.0771. 
A fraction enriched with (R)-3-Methyl-1,6-hexanedial (R-2-20) was prepared in the 
same way from (R)-(+)-citronellal (R-2-19). The product was used in the next step 
without further purification: [α]23D +8.4 (c 1.8, CHCl3); 1H-NMR (600 MHz, CDCl3) δ 
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0.95 (m, 3H), 1.47–1.56 (m, 1H), 1.69 (m, 1H), 1.95 (m, 1H), 2.16 (m, 1H), 2.30–2.44 
(m, 3H), 9.71 (brs, 1H), 9.73 (brs, 1H); 13C-NMR (200 MHz, CDCl3) δ 19.0, 27.1, 28.0, 
41.0, 50.2, 202.1, 202.2; HRFABMS calcd for C7H11O2 [M-H
-], 127.0765, found: 
127.0771. 
 
2.2.4.6. (6-Hydroxyhexyl)-triphenylphosphonium bromide (2-21) 
6-Bromo-1-hexanol (500 mg) and triphenylphosphine (800 mg) in MeCN (4 mL) were 
refluxed at 90 °C overnight. The reaction mixture was cooled to room temperature and 
concentrated. The resulting residue was dissolved in acetone and diluted with dry 
diethyl ether to precipitate the phosphonium salt. After stirring for 1 h, the precipitate 
was obtained by decantation and dried in vacuo to afford the desired phosphonium salt 
(2-21, 1.1 g) as white solids: [α]24D -0.65 (c 0.97, CHCl3); 1H-NMR (600 MHz, CDCl3) 
δ 1.43–1.77 (m, 8H), 2.03 (brs, 1H), 3.54–3.70 (m, 4H), 7.65–7.79 (m, 15H); 13C-NMR 
(200 MHz, CDCl3) δ 22.0 (d, J = 4.3 Hz), 22.2 (d, J = 49.9 Hz), 24.5, 29.3 (d, J = 15.9 
Hz), 31.7, 61.0, 118.0 (d, J = 86.0 Hz), 130.3 (d, J = 12.3 Hz), 133.3 (d, J = 10.1 Hz), 
134.8 (d, J = 2.2 Hz); HRFABMS calcd for C24H29OP [M
 +-Br] 363.1872, found: 
363.1869. 
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2.2.4.7. (S)-9-Methyl-6,12-octadecadiene-1,18-diol (S-2-22) 
To a suspension of 2-21 (250 mg) in dry THF (4 mL) was added LiHMDS (1.0 M in 
THF, 1.4 mL). The solution was stirred for 1h under nitrogen atmosphere, and then a 
solution of S-2-20 (15 mg) was added. The reaction mixture was stirred for 4 h, and 
NH4Cl saturated water was added and extracted with EtOAc. The organic layer was 
concentrated and purified by silica gel column chromatography (n-hexane/EtOAc 1:3) 
to give (S)-9-methyl-6,12-octadecadiene-1,18-diol (S-2-22, 11 mg) as a pale yellow oil: 
[α]23D +3.5 (c 0.48, CHCl3); 1H-NMR (600 MHz, CDCl3) δ 0.85 (d, J = 6.9, 3H), 
1.12–1.54 (m, 23H), 3.60 (t, J = 6.9, 4H), 5.31 – 5.38 (m, 4H); 13C-NMR (200 MHz, 
CDCl3) δ 19.5, 25.37, 25.39, 27.2, 27.3, 29.3, 29.4, 29.5, 32.56, 32.60, 33.0, 34.3, 36.6, 
62.8, 128.4, 129.5, 130.1, 130.4; HRFABMS calcd for C19H37O2 [M+H
+] 297.2788, 
found: 297.2788. 
(R)-9-Methyl-6,12-octadecadiene-1,18-diol (R-2-22) was prepared in the same way 
from R-2-20: [α]22D -4.3 (c 0.34, CHCl3); 1H-NMR (600 MHz, CDCl3) δ 0.85 (d, J = 6.9, 
3H), 1.12–1.58 (m, 23H), 3.62 (t, J = 6.9, 4H), 5.32–5.38 (m, 4H); 13C-NMR (200 MHz, 
CDCl3) δ 19.5, 25.3, 25.4, 27.0, 27.1, 29.2, 29.4, 29.5, 32.5, 32.9, 34.3, 36.6, 62.7, 
128.4, 129.5, 130.1, 130.4; HRFABMS calcd for C19H37O2 [M+H
+] 297.2788, found: 
297.2794. 
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2.2.4.8. (S)-9-Methyl-1,18-octadecanediol (S-2-18) 
S-2-22 (10 mg) was dissolved in methanol, and Pd/C (3 mg) was added to the solution. 
The suspension was stirred vigorously overnight under H2. The resultant mixture was 
filtered, and concentration of the filtrate afforded the diol (S-2-18, 7.0 mg) as colorless 
oil: [α]22D -0.52 (c 0.21, CHCl3); 1H-NMR (600 MHz, CDCl3) δ 0.81 (d, J = 6.9, 3H), 
1.24–1.33 (m, 20H), 1.54–1.65 (m, 11H), 3.62 (t, J = 6.9, 4H); 13C-NMR (200 MHz, 
CDCl3) δ 19.7, 25.70, 25.71, 25.72, 27.0, 29.38, 29.42, 29.50, 29.54, 29.59, 29.61, 
29.90, 29.94, 32.7, 32.8, 37.0, 63.0; HRFABMS calcd for 301.3101. found: 301.3122. 
R-2-18 was prepared in the same way using R-2-22: (R)-9-Methyl-1,18-octadecanediol 
(R-2-18); [α]23D +0.64 (c 0.14, CHCl3); 1H-NMR (600 MHz, CDCl3) δ 0.81 (d, J = 6.9, 
3H), 1.24–1.33 (m, 20H), 1.54–1.65 (m, 11H), 3.62 (t, J = 6.9, 4H); 13C-NMR (200 
MHz, CDCl3) δ 19.7, 25.70, 25.71, 27.0, 29.38, 29.40, 29.51, 29.55, 29.56, 29.60, 29.88, 
29.93, 32.8, 37.0, 63.0; HRFABMS calcd for C19H41O2 [M+H
+] 301.3101, found: 
301.3106. 
 
2.2.4.9. (1S, 2S)-15-diester of 2-18 derived from natural miyakosyne A 
To a solution of a 9-methyl-1,18-diol (2-18, 1 mg) in CH2Cl2, (1S,2S)-2-15 (1.2 mg), 
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1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydrochloride (1 mg), and 
N,N-dimethyl-4-aminopyridine (0.2 mg) were added and stirred for 4 h. The solution 
was concentrated and the residue was purified by HPLC (COSMOSIL 5SL-II) to afford 
(1S, 2S)-2-15-diester (0.2 mg) of 2-18, and a mixture of monoesters (0.2 mg). 
1H-NMR (600 MHz, CDCl3) of the (1S, 2S)-diester of 2-18 derived from miyakosyne A: 
δ 0.722 (d, J = 6.9 Hz, 3H), 0.85-1.60 (m, 37H), 1.82-1.89 (m, 6H), 2.12-2.15 (m, 2H), 
2.25 (dd, J = 3.6, 12.6 Hz, 2H), 3.50 (dt, J = 3.5, 11.8 Hz, 2H), 3.87 (dt, J = 1.4, 6.7 Hz, 
4H), 4.43 (dt, J = 4.0, 11.8 Hz, 2H), 7.58 (dd, J = 3.2, 6.4 Hz, 4H), 8.04 (dd, J = 3.3, 6.5 
Hz, 4H), 8.45 (s, 4H), 8.59 (s, 4H); HRFABMS calcd for C65H75N2O8 [M+H
+] 
1011.5523, found: 1011.5532. 
 
2.2.4.10. (1S, 2S)- 2-15-diester of S-2-18 
(1S, 2S)-2-15-diester of S-2-18 was prepared in the same way using S-2-18: 1H NMR 
spectrum was almost superimposable on that of (1S, 2S)-2-15-diester of 2-18 except for 
the branched methyl (δ 0.720); HRFABMS calcd for C65H75N2O8 [M+H+] 1011.5523, 
found: 1011.5512. 
 
2.2.4.11. (1S, 2S)-2-15-diester of R-2-18 
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(1S, 2S)- 2-15-diester of R-2-18was prepared in the same way using R-2-18: (1S, 2S)- 
2-15-diester of R-2-18: 1H NMR was almost superimposable on that of (1S, 2S)- 
2-15-diester of 2-18 (chemical shift of the branched methyl δ 0.722); HRFABMS calcd 
for C65H75N2O8 [M+H
+] 1011.5523, found: 1011.5573. 
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Chapter 3. 
Poecillastrin C and its analogue, potent cytotoxic macrolide lactams, from a 
deep-sea marine sponge. 
 
 
 
3. 1. Introduction 
Deep-sea sponges and microorganisms are intriguing target for the discovery of 
new bioactive compounds. The environment of the deep-sea is very different from that 
of shallow water in terms of sun light, temperature, and water pressure. Therefore, 
deep-sea inhabitants are thought to inherit distinct genome and produce unique 
secondary metabolites. Recent advances of collecting deep-sea organisms enabled us to 
investigate the bioactive compounds from deep-sea sponges or bacteria. A number of 
deep-sea derived marine natural products were isolated.1, 2 Chondropsin/poecillastrin 
type of macrolide lactams are one of the typical deep-sea sponge derived metabolites.3-9 
These macrolide lactams exhibited potent antitumor activity and inhibited vacuolar type 
(H+)-ATPase.10 
During the course of our screening for cytotoxicity of sponge metabolites, an 
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unidentified deep-sea sponge S09-1060-01 exhibited potent cytotoxicity against HeLa 
cells. Bioactivity-guided fractionation of the extract resulted in the isolation of new 
poecillastrin analogue termed poecillastrin E (3-1) together with the known poecillastrin 
C (3-2). 
 
 
 
3. 2. Results and Discussion 
The extract of an unidentified marine sponge S09-1060-01 was partitioned 
between H2O/CHCl3, and aqueous layer was concentrated and partitioned between 
H2O/n-BuOH. The organic layer was concentrated and partitioned between 90 % 
MeOH/n-hexane, respectively. The n-BuOH and 90 % MeOH fractions were combined 
and subjected to ODS column chromatography. Bioactive fraction was purified by 
reversed phase HPLC to afford compounds 3-1 and 3-2. 
The molecular formula of 3-1 was determined to be C78H127N3O20 by 
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HRESIMS (1448.8923 [M+Na]+, calcd for C78H127N3O20Na, 1448.8911). 
1H NMR and 
HSQC spectra of 1 resembled those of poecillastrin C. With this structural similarity in 
mind, 1D and 2D NMR spectra of 3-1 were analyzed. Detailed analysis of COSY and 
TOCSY spectra together with HMBC spectra revealed that 3-1 had the identical carbon 
skeleton with that of poecillastrin C, with the exception of the presence of pentaen 
moiety (Figure 3-1, Table 3-1). UV absorption at λ 356 nm validated the assignment of 
the pentaen structure. 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. COSY and TOCSY correlations (bold lines) and key HMBC correlations 
(arrows) of poecillastrin E (3-1). 
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Table 3-1. 1H and 13C NMR data of Poecillastrin E (3-1) in CD3OD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. δH, mult. δC No. δH, mult. δC
1 174.2 41 5.18, d (10.7) 78.2
2 4.92 57.4 42 4.14, d (5.0) 54.7
3 43
4 168.2 44 178.6
5 6.19, d (15.0) 124.9 45 2.56 48.3
6 7.24, dd (11.3, 15.0) 142.3 46 3.56 74.2
7 6.47, dd (9.8, 14.8) 131.4 47a 1.48 33.0
8 6.74 dd (11.1, 14.8) 141.3 47b 1.57
9 6.45, dd (11.1, 14.9) 133.4 48a 1.22 29.7
10 6.65, dd (10.8, 14.9) 138 48b 1.35
11 6.46, dd (10.8, 14.5) 133.9 49 1.64 36.5
12 6.55, dd (10.6, 14.5) 136.2 50 3.66, brd (8.3) 83.9
13 6.49, dd (10.6, 14.6) 135.7 51 137.6
14 5.68 dd (9.6, 14.6) 135.4 52 5.37, d (9.9) 131.1
15 3.99, t  (9.6) 81.7 53 2.62 36.1
16 3.63 75.8 54 3.37 78.7
17a 1.21 34.6 55 4.05 51.3
17b 1.88 56
18 1.86 27.2 57 167.0
19a 0.90 41.4 58 6.10, d (15.7) 124.0
19b 1.49 59 6.94, d (15.7) 148.3
20 3.54 69.4 60 51.6
21a 1.12 43.3 61 216.7
21b 1.39 62 3.14, dd (6.6, 9.7) 45.6
22 4.01, q (7.0) 66.0 63 3.56 77.9
23 1.30 42.4 64 1.78 30.0
24 3.48, d (9.9) 80.7 65 0.96 20.4
25 137.0* 66 0.94 22.7
26 4.89 135.1 67 3.74 69.7
27 2.50 35.8 68 1.17, d (6.2) 21.4
28 3.44 84.1 69 1.18 15.6
29 137.1 70 0.97 15.9
30 5.22, brt (5.4) 128.7 71 1.55 11.9
31a 1.91 34.6 72 1.01, d (7.0) 17.7
31b 2.29 73 1.49 40.2
32 3.44 69.5 74 1.59 25.8
33 4.88 72.8 75 0.93 21.9
34 175.3 76 0.93 24.3
35 0.93 22.7 77 1.28 23.9
36 0.50, d (7.0) 8.6 78 1.31 23.9
37 1.54 10.4 79 0.88 15.7
38 0.54, d (7.0) 17.5 80 0.85, d (6.6) 14.2
39 1.58 11.2 15-OMe 3.26 56.4
40 1.78 40.6
Poecillastrin E (3-1)
1
H NMR apectrum was measured at 600 MHz, δC was assigned by HSQC data.
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The geometries of its pentaene portion were determined to be all E by large 
3JHH coupling constants between H5/H6, H7/H8. H9/H10, H11/H12 and H13/H14, 
which was confirmed by a series of NOE correlations between H6/H8, H8/H10, 
H10/H12, and H12/H14. NOE correlations between H24/H26, H28/H30, and H50/H52 
established the E configuration of olefins at Δ25, 26, Δ29, 30, andΔ51, 52. 3JH58H59 of 15.6 Hz 
confirmed the E-geometry at Δ58, 59. Finally, the planar structure of 3-1 was confirmed to 
be the hybrid type of poecillastrin C and mirabalin, and 3-1 was named as poecillastrin 
E. Polyene macrolactam structure was reported to be unstable under the light, and 3-1 
decomposed under the ambient light condition.9 The molecular weight, NMR spectra, 
specific rotation, and retention time in HPLC of compound 3-2 were identical with 
those of poecillastrin C. Therefore, 3-2 was identified as poecillastrin C (Table S3-1).7, 8 
Neither the relative configuration nor the absolute configuration of 
chondropsin/poecillastrin class of compounds have been completed because of the 
complexity of the molecule and limited amount of the sample. In this study, the relative 
configurations of the partial structures of 3-2 were investigated based on the 
interpretation of NOESY and DQF-COSY data. First, the configuration of 
tetrahydropyrane ring was examined by NOESY data. H15 exhibited NOE correlations 
to H18 and H20, pointing out the axial orientation of the alkyl substituent at C16. 
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Another NOE correlation between H18 and H20 supported the 1,3-diaxial relationship. 
Analysis of coupling constants and NOESY spectra revealed the relative configurations 
of C20/C21, and C21/C22. A large coupling constant between H20 and H21a (8.4 Hz) 
indicated their anti relationship, and NOESY correlations between H19 and H21b, and 
H20 and H22 assigned the relative configuration of C20/C21 (Figure 3-2a). The relative 
configuration of C21/C22 was assigned by a 3JH21bH22 value of 10.5 Hz and NOE 
correlations between H21ab and Me36 (Figure 3-2b). The anti configuration of Me36 
and hydroxyl group at C24 was apparent from a large 3JH21bH22 value of 10.8 Hz and 
NOE correlation from Me36 to Me37 and H26 (Figure 3-2c). Generally, the relative 
configuration of 2-methyl-1,3-diol spin system (C22/C23/C24) could be determined by 
comparison of the 13C NMR chemical shift of the methyl carbon with Kishi’s universal 
NMR database, in which 7.1 ppm represents for syn/syn configuration, 10.7 ppm for 
syn/anti or anti/syn configuration, and 11.6 ppm for anti/anti configuration.11 However, 
an intermediate chemical shift at δC 8.6 ppm of Me36 was not appropriate for the 
assignment of the relative configuration in this molecule. The relative configuration 
between C27 and C28 was also assigned by the large coupling constant between H27 
and H28, and NOE correlation between Me38 and Me39 (Figure 3-2d). NOE 
correlations observed from H32 to H40 and H41, and from H31 to H40 and Me66 
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assigned the relative configuration at C32/C40 (Figure 3-2e). The relative configuration 
at C40/C41 was established from a large coupling constant between H40 and H41 
together with NOE correlation between Me66 and H42 (Figure 3-2f). The relative 
configuration at C41/C42 was determined by the small 3JH41H42 of 1.4 Hz and NOE 
correlations between H41/H67 and Me66/H42 (Figure 3-2g). Me79 and hydroxyl group 
at C63 was assigned to be anti from a large 3JH62H63 and NOE correlation between Me79 
and H64 (Figure 3-2h). The modified Mosher’s method was attempted to determine the 
absolute configuration of the chiral center substituted to the secondary alcohol, however 
we ended up with the dehydration of the compound.12 
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Figure 3-2. Conformational analysis of poecillastrin C for assignment of the relative configuration 
of (a) C20/C21, (b) C21/C22, (c) C23/C24, (d) C27/C28, (e) C32/C40, (f) C40/C41, (g) C41/C42, 
(h) C62/C63. NOESY correlations were illustrated as arrows. 
 
 Chondropsin/poecillastrin type of macrolide lactams are reported to inhibit 
vacuolar-type (H)+-ATPase and show potent cytotoxicity against various type of cancer 
cells.3-10 HeLa cells treated with poecillastrins C or E at concentrations ranging from 4 
ng/mL to 100 ng/mL did not show cell growth and died in 2 days. Poecillastrins E (3-1) 
exhibited potent cytotoxicity against HeLa cells with an IC50 value of 1.8 ng/mL, of the 
IC50 value of poecillastrin C (3-2) was 0.99 ng/mL.  
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3.3. Experimental Section 
3.3.1. General Experimental Procedures. 
Optical rotations were measured on a JASCO DIP-1000 digital polarimeter in MeOH. 
NMR spectra were recorded on a JEOL alpha 600 NMR spectrometer at 300 K. 
Chemical shifts were referenced to solvent peaks: δH3.30 and δc49.0 for CDCl3. ESI 
mass spectra were measured on a JEOL JMS-T100LC. 
 
3.3.2. Animal Material. 
An unidentified marine sponge S09-1060-01 was collected at Miyako sea-knoll, 
southwestern Japan by using the Remotely Operated Vehicle ‘Hyper-Dolphin’ in 
October 2009during a cruise of R/V Natsushima, 
 
3.3.3. Extraction and Isolation. 
The frozen marine sponge (600 g) was extracted with 1.8 L of 50 % MeOH, and EtOH. 
The crude extracts were combined and partitioned between H2O and CHCl3. The 
aqueous layer was extracted with n-BuOH. The organic layer was concentrated in vacuo 
and partitioned with 90 % MeOH and n-hexane. n-BuOH and 90 % MeOH layers were 
combined, concentrated and fractionated by ODS column chromatography eluted with 
100 
 
50 % MeOH, 70 % MeOH, 90 % MeOH, MeOH, and a mixture of CHCl3, MeOH and 
H2O (6:4:1). 70 % MeOH fraction was concentrated and purified by reversed phase 
HPLC with a linear gradient from MeCN/H2O (11:9) containing 1 % AcOH to 
MeCN/H2O (7:3) containing 1 % AcOH to afford 2.5 mg of 3-1 and 2.8 mg of 3-2. 
3.3.1. Poecillastrin E (3-1): pale yellow solid; [α]18D +28 (c = 0.15, MeOH); UV 
(MeOH) λmax 373 (17,000), 356 (20,000), 205 (18,000);1H and 13C NMR data, see 
table 1; HRESIMS m/z 1448.8923 [M+Na]+, calcd for C78H127N3O20Na, 1448.8911. 
 
3.3.4. Cytotoxicity Evaluation. 
The cytotoxicities of 3-1 and 3-2 against HeLa cells were evaluated by an MTT assay. 
HeLa human cervical cancer cells were cultured in Dulbecco’s modified Eagle’s 
medium containing 10% fetal bovine serum, penicillin and streptomycin at 37°C under 
an atmosphere of 5% CO2. After overnight preincubation, sample was added to each 
well of a 96-well microplate containing 200 μL of tumor cell suspension (1 x 104 
cells/mL), and further incubated for 72 h. MTT saline solution was added to each well, 
and the plate was incubated for 3 h. The supernatant was discarded and formazan dye 
was dissolved in 150 μL of DMSO. The absorbance was measured to determine IC50 
values.   
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Table S3-1. 1H and 13C NMR chemical shifts of poecillastrin C (3-2). 
 
No. δH δC No. δH δC
1 174.6 41 5.16 78.1
2 4.87 57.5 42 4.14 54.6
3 43
4 168.4 44 178.6
5 6.11 123.9 45 2.54 48.3
6 7.14 142.2 46 3.55 74.1
7 6.32 129.8 47a 1.46 32.9
8 6.22 143.1 47b 1.56 32.9
9 2.34 35.0 48a 1.20 29.6
10 2.23 33.5 48b 1.46 29.6
11 5.87 135.9 49 1.63 36.5
12 6.32 131.6 50 3.65 83.9
13 6.33 135.8 51 137.4
14 5.56 131.9 52 5.36 131
15 3.93 81.7 53 2.61 36.0
16 3.63 75.7 54 3.36 78.6
17a 1.21 34.5 55 4.04 51.2
17b 1.88 34.5 56
18 1.86 26.7 57 167.2
19a 0.89 41.3 58 6.07 123.9
19b 1.52 41.3 59 6.93 148.3
20 3.52 68.8 60 51.9
21a 1.15 42.9 61 216.8
21b 1.44 42.9 62 3.13 45.5
22 4.21 65.9 63 3.55 78.4
23 1.39 41.7 64 1.77 29.9
24 3.74 81.2 65 0.86 14.1
25 136.9 66 0.93
26 5.00 135.3 67 3.73 69.8
27 2.51 35.9 68 1.16 21.1
28 3.48 84.4 69 1.18 15.4
29 137.2 70 0.97 15.8
30 5.24 128.6 71 1.55 11.8
31a 1.91 34.4 72 1.00 17.6
31b 2.28 34.4 73 1.49 40.2
32 3.46 69.7 74 1.56 25.7
33 4.85 72.9 75 0.92 21.8
34 175.9 76 0.92 24.2
35 0.93 22.6 77 1.27 23.7
36 0.55 8.6 78 1.30 23.8
37 1.57 10.4 79 0.89 15.5
38 0.60 17.4 80 0.95 20.4
39 1.58 10.6 15-OMe 3.23 56.1
40 1.79 40.4
Poecillastrin C (3-2)
1
H NMR spectrum was measured at 600 MHz,
δC was assigned by HSQC data.
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Figure S3-1. 1H NMR spectrum of 3-1 
 
Figure S3-2. COSY spectrum of 3-1. 
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Figure S3-3. DQF-COSY spectrum of 3-1. 
 
Figure S3-4. TOCSY spectrum of 3-1. 
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Figure S3-5. HSQC spectrum of 3-1. 
 
Figure S3-6. HMBC spectrum of 3-1. 
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Figure S3-7. NOESY spectrum of 3-1. 
 
Figure S3-81H NMR spectrum of 3-2. 
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Figure S3-9. DQF-COSY spectrum of 3-2. 
 
Figure S3-10. TOCSY spectrum of 3-2. 
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Figure S3-11. HSQC spectrum of 3-2. 
 
Figure S3-12. HMBC spectrum of 3-2. 
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Figure S3-13. NOESY spectrum of 3-2. 
 
 
 
 
Figure S3-14. Photograph of an unidentified marine sponge S09-1060-01. 
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Chapter 4. 
Introduction of fluorescent time-lapse imaging of HeLa/Fucci2 cells for 
 the identification of cell cycle arrest inducers 
 
 
4.1. Screening of cell cycle arrest inducers. 
 
4.1.1. Introduction 
  A wide variety of anticancer agents induce cell death by affecting replication of 
DNA or microtubule dynamics, which play key roles in the cell cycle progression.1 The 
perturbation of the control of cell division results in the induction of cell cycle arrest 
and apoptosis. Therefore, metabolites that induce cell cycle arrest can be candidates for 
leads compounds for anticancer agents. The conventional way to analyze the cell cycle 
progression requires measurement of cellular DNA content by flow cytometory.2 
Because, this method is low throughput, it is not suitable for the screening of a large 
number of extracts.  
Fucci (Fluorescent Ubiquitination-based Cell Cycle Indicator) developed by 
RIKEN is the dual-color fluorescent probe which enables the real-time imaging of the 
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cell cycle progression.3 Fucci2, a second generation of Fucci probe, was developed by 
fusing a red fluorescent protein (mCherry) and green fluorescent protein (mVenus) to 
the ubiquitination domain of human Cdt1 and Geminin, respectively.4 Cdt1 is DNA 
replication factor, and is accumulated inside the nuclei at G1 phase and degraded at S 
phase.5 On the other hand, Geminin, DNA replication inhibitor, accumulates inside the 
nuclei through S to M phases and degraded during mitosis.5 As a result, red fluorescent 
protein accumulates inside the nuclei of cells at G1 phase, and green fluorescent protein 
accumulates through S/G2/M phase in Fucci2 transfected cells (Figure 4-1). Hence, the 
time-dependent change of cell cycle progression can be visualized at the single cell 
level. In this study, I applied time-lapse imaging of Fucci2 transfected HeLa cells 
(HeLa/Fucci2) and examined the effects of a library of marine natural products crude 
extracts of marine organisms. 
 
  
111 
 
 
 
 
 
 
 
 
Figure 4-1. (a) Scheme of the cell cycle progression of HeLa/Fucci2 cells. (b) 
Fluorescence image of HeLa/Fucci2 cells. (c) Time-dependent change of cell cycle 
progression of HeLa/Fucci2 cells. 
 
4.1.2. Results and Discussion 
First, 27 pure marine natural products were evaluated in the HeLa/Fucci2 assay. 
The compounds tested in this study are as follows:13-deoxytedanolide,6 purpuramine,7 
theonellamide A,8 curcuphenol,9 tetrapyrrol,10 dibromophakellin,11 mycalolide A,12 
onnnamide B,13 misakinolide A,14 rubroside F,15 halistanolsulfate,16 bistellettadine A,17 
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koshikamide A,18 dogger bank itch,19 penarolide sulfate A1,
20 penarolide sulfate A2,
20 
discodermine A,21 polytheonamide A,22 aurantoside A,23 stellettadine A,24 corticatic 
acid,25 aerothionine,26 stelliferin E,27 toxadocial A,28 petrosynol,29 oroidin,30 and 
cylindramide31 (Table 4-1). Several compounds exhibited acute cytotoxicity at higher 
concentrations and induced cell death within a few hours. Notably, HeLa/Fucci2 cells 
treated with onnamide B at lower concentrations showed time-dependent characteristic 
phenotypical change (Figure 4-2). From several hours after treatment of the compound, 
green fluorescence gradually increased inside the nuclei, and resulted in cell death. 
Onnamide B, a member of pederin family, is known to inhibit the protein synthesis by 
targeting the ribosomal E-site.13 Inhibition of ribosomal protein synthesis by onnamide 
B induces activation of stress-activated protein kinases.32 These molecular mechanism 
resulted in the induction of cell cycle arrest at S/G2 phase and cell death. 
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Table 4-1. List of the pure marine natural products assayed by the time-lapse imaging of 
HeLa/Fucci2 cells. 
13-Deoxytedanolide 
 
Cytotoxicity 
Purpuramine 
 
- 
Theonellamide A 
 
Vacuole 
formation 
Curcuphenol 
 
- 
Tetrapyrrol 
 
Cytotoxicity 
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Dibromophakellin 
 
Cytotoxicity 
Mycalolide A 
 
Morphological 
change 
(Figure 4-1-3) 
Onnamide B 
 
Mitotic arrest 
(Figure 4-1-2) 
Misakinolide A 
 
Morphological 
change 
(Figure 4-1-3) 
Rubroside F 
 
Cytotoxicity 
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Halistanol sulfate 
 
- 
Bistellettadine A 
 
- 
Koshikamide A 
 
Cytotoxicity 
Dogger bank itch 
 
Mitotic arrest 
Penarolide sulfate A1 
 
Cytotoxicity 
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Penarolide sulfate A2 
 
Cytotoxicity 
Discodermine A 
 
Cytotoxicity 
Polytheonamide A 
 
Cytotoxicity 
Aurantoside A 
 
Cytotoxicity 
Stellettadine A 
 
- 
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Corticaic acid 
 
- 
Aerothionine 
 
- 
Stelliferin E 
 
Cytotoxicity 
Toxadocial A  Cytotoxicity 
Petrosynol 
 
- 
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Oroidin 
 
- 
Cylindramide 
 
Vacuole 
formation 
 
 
 
Figure 4-2. Typical fluorescent images of HeLa/Fucci2 cells treated with 0.3 μg/mL of 
onnamide B. 
 
 
Mycalolide A and misakinolide A, whose molecular target is actin, induced 
characteristic morphological changes of HeLa/Fucci2 cells. Mycalolide A is a 
trisoxazole macrolide isolated from a marine sponge Mycale sp.12 Mycalolide A binds to 
G-actin and severs and depolymerizes F-actin.33 HeLa/Fucci2 cells treated with 
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mycalolide A were inhibited in cytokinesis and led to endoreplication and polyploid 
formation (Figure 4-3). Misakinolide A also depolymerized actin cytoskeleton and 
induced polyploidal giant cells (Figure 4-3).14 
 
 
Figure 4-3. Fluorescent microscopic images of HeLa/Fucci2 cells treated with 8 ng/mL 
of mycalolide A (Left), and 12 ng/mL of misakinolide A (Right). 
 
Then, biological activity of the crude extract library of marine invertebrates 
was evaluated by the time-lapse imaging assay of HeLa/Fucci2 cells. Approximately 
800 crude extracts of marine invertebrates collected between 1997 and 2013 were tested. 
20 samples potently induced cell cycle arrest at S/G2 phase. The crude extracts of 
unidentified marine sponges S01-162 and S09-1060-15 induced inhibitory activity of 
mitosis. Bioactivity-guided fractionation of the marine sponge S01-162 afforded a 
potent cell cycle arrest inducing compound. The bioactive compound was identified as 
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meridine, an antifungal pyridoacridine compound, by comparing the NMR 
spectroscopic data with those in the literature (Figure 4-4A).34 Another marine sponge 
S09-1060-15 also contained meridine and its congeners. HeLa/Fucci2 cells treated with 
meridine were at S/G2phase within 12 hours and entered endorepliction cycle (Figure 
4-4B). This phenotypical change was similar to that treated with antitumor agents, 
doxorubicin and etoposide (Figure 4-4A), whose modes of action are DNA intercalation 
and inhibition of DNA topoisomerase II, respectively.35 The DNA-directed activity and 
topoisomerase II inhibitory activity of pyridoacridines were reported. Therefore, it is 
well expected that meridine induces cell cycle arrest at S/G2 phase.36 
 
4.1.3. Conclusion 
 Fluorescent time-lapse imaging of HeLa/Fucci2 cells enabled the identification 
of the inhibitor of cell cycle progression, as well as bioactive compounds that change 
the morphology of the cells. This cell-based assay gives much more information on the 
bioactivity than the conventional cell viability assays. Therefore, this assay will be an 
efficient method that detects metabolites affecting one or more points in the cell cycle 
progression.   
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B 
 
 
 
 
 
 
 
 
Figure 4-4. Investigation of mitosis inhibitor from marine sponges. (A) Chemical 
structures of meridine, doxorubicin, and etoposide. (B) Fluorescent time-lapse images 
of HeLa/Fucci2 cells treated with 2 μg/mL of meridine, 0.7 ng/mL of doxorubicin, and 2 
μg/mL of etoposide.   
0 h 12 h 48 h 72 h
Meridine
Doxorubicin
Etoposide
Meridine Doxorubicin Etoposide 
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4.1.4. Experimental section 
4.1.4.1. General Experimental Procedures. 
NMR spectra were recorded on a JEOL alpha 600 NMR spectrometer. ESI mass 
spectra were measured on a Bruker AmaZon SL. Time-lapse imaging of cells was 
conducted on the Essen bioscience IncuCyte Zoom. 
 
4.1.4.2. Cell Culture and time-lapse imaging assay. 
HeLa/Fucci2 cells were purchased from RIKEN Bio Resource Center CELL BANK 
and grown in FluoroBrite DMEM media (life technologies) supplemented with 10 % 
fetal bovine serum, 4 mM L-glutamine, 100 units/mL penicillin and 0.1 mg/mL 
streptomycin. Cells were seeded into 96 multi well plates (1.0 x 105 cells in 200 μLof 
medium). After overnight preincubation, cells were treated with 2 μL of MeOH solution 
of tested sample and incubated for 3 days. Fluorescent microscopic images were taken 
every two hours. 
 
4.1.4.3. Extraction and Isolation of meridine. 
The frozen marine sponge (120 g) was extracted with EtOH and mixture of MeOH 
/CHCl3 (1:1). The crude extract was concentrated and partitioned between H2O and 
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CHCl3. The organic layer was further partitioned between 90 % MeOH and n-hexane. 
The 90 % MeOH layer was concentrated and fractionated by ODS column 
chromatography eluting with 70 % MeOH, 90 % MeOH, MeOH, and mixture of 
CHCl3/MeOH/H2O (14:6:1). 70 % MeOH fraction was concentrated and purified by 
ODS HPLC (COSMOSIL AR-II; 10 x 250 mm) with linear gradient from 20 % MeCN 
to 50 % MeCN to afford meridine (0.9 mg). 
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4.2. Isolation and structure elucidation of novel terpene quinones as cell cycle 
arrest inducers. 
 
 
4.2.1. Introduction 
Mitosis and cytokinesis are the primordial cellular mechanisms to distribute the 
identical genome to two daughter cells. The cell cycle consists of four stages, G1, S, G2 
and M phases, and their progression was elaborately regulated by the intricate 
checkpoint systems governed by Cdks (cyclin-dependent kinases), p53, and ATM.37 
However, cancer cells lacks these checkpoint functionalities and undergo unrestricted 
cell proliferation. Numbers of clinically used antitumor drugs directly inhibit the cell 
cycle progression of cancer cells by disturbing spindle assembly, DNA replication, and 
cytokinesis.38 Therefore, investigation of marine natural products which induce cell 
cycle arrest may lead to the discovery of leads compounds for developing new 
antitumor drugs. Fucci (Fluorescent Ubiquitination-based Cell Cycle Indicator) enables 
the fluorescent visualization of cell cycle progression in living cells.3,4 In this study, we 
investigated the marine natural products that induce cell cycle arrest by using the 
time-lapse assay of HeLa/Fucci2 cells. 
In the course of searching for marine sponge metabolites that inhibit cell cycle 
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progression against HeLa/Fucci2 cells, the crude extract of an unidentified marine 
sponge S09-1061-2 induced mitotic arrest. Bioassay-guided fractionation of the extract 
afforded two novel terpene quinones termed metachromins X and Y (4-1, 4-2) together 
with the known metachromins C (4-3), J (4-4) and T (4-5).39-41 Further investigation of 
bioactive compounds that inhibit mitosis from other sponges resulted in the isolation of 
another terpene quinone analogue 5-epi-isospongiaquinone (4-6) from an unidentified 
sponge S13-013. Evaluation of the biological activities of these compounds revealed 
that all of them exhibited moderate cytotoxicity against HeLa/Fucci2 cells, and 
metachromin X (4-1), metachromin C (4-3), and 5-epi-isospongiaquinone (4-6) induced 
mitotic arrest. 
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4.2.2. Results and Discussion 
The MeOH extract of the marine sponge S09-1061-02 was partitioned between 
CHCl3 and H2O. The organic layer was concentrated and partitioned between 90% 
MeOH and n-hexane. The 90% MeOH fraction was subjected to ODS flash column 
chromatography, and the bioactive fraction was purified by RP-HPLC to afford 
compounds 4-1 and 4-2 together with known terpene quinones, metachromins C (4-3), J 
(4-4), and T (4-5).39-41 
 The molecular formula of 4-1 was determined to be C22H30O4 by HRESIMS 
[m/z 381.2051, (M+Na)+, Δ0.9 mmu]. Interpretation of the 1H NMR spectrum in 
conjunction with the HSQC spectrum revealed the presence of two aliphatic methyls, 
two vinylic methyls, one methoxy group, six methylenes, two olefinic protons, and one 
hydroxyl proton. 13C NMR spectrum showed two quinone signals at δ181.1 and 182.6, 
two oxygenated aromatic signals at δ150.8 and 160.6, and four olefinic carbon signals 
between δ 126.4-138.1. The presence of trisubstituted1,4-benzoquinone moiety was 
confirmed by the HMBC correlations from H19 (δ 5.82) to C17 (δ 150.8), C20 (δ 
160.6), and C21 (δ 181.1), from phenolic proton (δ 7.22) to C17, and C18 (δ 182.6), and 
from methoxy protons (δ 3.84) to C20 (Figure 4-5). Three spin systems, H2-H4, H7-H8, 
and H10-H11, inferred by COSY correlations were connected with each other based on 
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the HMBC correlations, and the monocyclic sesquiterpene moiety was assigned. HMBC 
correlations from H11 to C16 (δ 138.1) and C21 (δ 181.5) established the linkage 
between sesquiterpene moiety and the benzoquinone ring system via C11-C16 bond. 
The E geometry of the double bond at C9 was determined by the NOESY correlation 
between H8 and H10 (Figure 4-5).  
 
 
 
Figure 4-5. COSY (bold lines) and key HMBC correlations (arrows) in 4-1. 
 
 Compound 2 had a molecular formula of C20H28O4 as assigned by HRESIMS. 
The 1H NMR, HSQC, COSY, and HMBC spectra of 4-2 confirmed that 4-1 and 4-2 
shared the common cyclohexene ring system. The mutually coupled Z-olefin protons of 
H10 and H11 at δ 5.53 and 6.48 (3JHH= 10.3 Hz) were connected to the benzoquinone 
ring via the C11-C16 bond, which was inferred from the HMBC correlations between 
H10 and C16 and between H11 and both C17 and C21. Furthermore, HMBC 
correlations from the olefinic protons to a quaternary carbon C9 (δ 83.4) revealed the 
pyrane fused to the benzoquinone via an ether bond between C9 and C21. A singlet 
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methyl proton showed HMBC correlations to C8 and C9, permitting us to complete the 
assignment of the planer structure of compound 4-2 (Figure 4-6).  
 
 
Figure 4-6. COSY (bold lines) and key HMBC correlations (arrows) in 4-2. 
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Table 4-2. 1H NMR and 13C NMR chemical shifts of 4-1 and 4-2 
 
In order to determine the enantiomeric purity of compound 4-2, chiral HPLC 
analysis was conducted.42 Prior to the analysis of 4-2, a racemic mixture of 
trimethoxychromenol 4-7 was prepared from 4-1 according to the Kobayashi’s 
method.43 HPLC separation (Chiral OJ-RH) of the racemic mixture of 4-7 afforded two 
peaks for each enantiomer (Figure 4-7). Generally, in the CD spectrum of chromenols, 
strong Cotton effect is observed around the 260-270 nm region due to the skewed 
position δH δC δH δC
1 34.9 127.7
2 1.38 (m) 39.8 1.85 (t, 6.6) 32.7
3 1.53 (m) 19.5 1.51(m) 19.7*
4 1.87 (t, 6.9) 32.7 1.36 (m) 39.7
5 126.9 35.0
6 136.9 135.8
7 1.99 (m) 27.6 2.07 22.3
8 1.97 (m) 40.1 1.70 (m) 41.6
1.86 (m)
9 138.2 84.0
10 5.13 (t, 6.3) 118.7 5.53 (d, 10.3) 127.7
11 3.14 (d, 7.6) 21.7 6.48 (d, 10.3) 115.2
12 0.95 (s) 28.6 1.52 (s) 19.4*
13 0.95 (s) 28.6 0.93 (s) 28.56
14 1.55 (s) 19.8 0.90 (s) 28.6
15 1.77 (s) 16.2 1.47 (s) 27.1
16 138.2 113.5
17 151.2 178.5
18 182.9 158.8
19 5.82 (s) 102.2 5.78 (s) 105.3
20 161 181.3
21 181.5 151.9
OMe 3.84 (s) 56.7 3.79 (s) 56.4
metachromin Y (2)metachromin X (1)
1
H and 
13
C NMR at 600 MHz and 150 MHz in CDCl3, *Assignments may be
interchanged
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styrene chromophore. The right-handed helix shows strong negative Cotton effect and 
the left hand helix positive cotton effect.44 In compound 4-7, the bulky side chain 
generates steric hindrance to the chromenol ring and prefers the pseudoequatrial 
orientation.45 Therefore, the absolute configuration of the chiral center at C9 in 4-7 
could be deduced from the CD spectral data (Figure 4-7). Then, 4-2 was converted to 
4-7, and subjected to the chiral HPLC, which gave two pronounced peaks, suggesting 
that 4-2 was a racemic mixture (Figure 4-8). By altering the stationary phase to chiral 
OJ, 4-2 could be directly separated into enantiomers, confirming that 4-2 was a racemic 
mixture. 
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Figure 4-7. CD spectra of R-4-7 and S-4-7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8. Chiral HPLC chromatograms of compound 4-7 prepared from (a) 4-1, (b) 4-2, and (c) 
coinjection of them. 
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 Sesquiterpene quinones are characteristic matabolites of marine sponges. In 
particular, sesquiterpene quinones containing a decalin ring were intensively studied as 
to their structural diversity and biological activities.46 A further investigation of the 
extract of another marine sponge led to the isolation of 5-epi-isospongiaquinone (4-6) 
from an unidentified marine sponge S13-013. 4-6 was first reported as the antibiotic 
compound isolated from an Australian sponge Spongiabispida, and consisted of the 
clerodane-type decalin ring.47 With metachromins (4-1 - 4-5) and 
5-epi-isospongiaquinone (4-6) in hand, their biological activity against HeLa/Fucci2 
cells was evaluated. Compounds 4-1 - 4-6 exhibited moderate antiproliferative activity 
with IC50 values of 10, 21, 19, 12, 18, 6.3 μg/mL, respectively. Interestingly, 
enantiomers of 4-2 exhibited equipotent biological activity. Notably, time-lapse imaging 
of HeLa/Fucci2 cells revealed that compound 4-1, 4-3, and 4-6 induced cell cycle arrest 
at S and G2 phase, whereas other compounds did not induce mitotic arrest (Figure 4-9).  
Terpene quinones were reported to exhibit a broad spectrum of biological 
activities, such as antitumor, antiviral, and anti-inflammatory. Their diverse biological 
activities were attributed to two general mechanism46 1) redox cycling of quinone 
causes the production of reactive oxygen species which damage mitochondria and 
biomolecules; 2) electron arylation of cellular nucleophiles which induce disorder of 
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cellular function. It is conceivable that reactive oxygen species produced through redox 
cycling of terpene quinones damaged DNA and induced cell cycle arrest, and/or terpene 
quinones broadly arylated cellular molecules regulating cell cycle progression, and 
induced cell cycle arrest. The results of this study implicate that the 
2-hydroxy-5-methoxy-1,4-benzoquinone moiety is required for the mitotic arrest. 
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Figure 4-9. Evaluation of biological activities of terpene quinones. (A) Fluorescent microscopy 
images of HeLa/Fucci2 cells treated with 20 μg/mL of 4-1, 4-2, and 4-6, and MeOH as control. Red 
and green fluorescence represents cells at G1 and S/G2/M phase, respectively. Pictures were taken 
after 68 h incubation. (B) Flow cytometry of HeLa/Fucci2 cells. Distribution of the HeLa/Fucci2 
cells in G1 phase was decreased by the treatment of 4-1. 
  
Control 20 μg/mL of 1 
G1 S/G2 M G1 S/G2 M 
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4.2.3. Conclusion 
Herein, I report the time-lapse imaging assay using HeLa/Fucci2 cells to 
investigate bioactive marine natural products that induce mitotic arrest. As a result, two 
new metabolites, metachromins X (4-1) and Y (4-2), together with the known 
metachromins C (4-3), J (4-4), and T (4-5) were isolated from a marine sponge 
S09-1061-02. Additionally, another terpene quinine, 5-epi-isospongiaquinone (6) was 
isolated from a marine sponge S13-013. Compounds 4-1, 4-3, and 4-6 induced mitotic 
arrest of HeLa/Fucci2 cells. The structure activity relationship of these terpene quinones 
revealed that the 2-hydroxy-5-methoxy-1,4-benzoquinone ring was responsible for the 
inhibition of the cell cycle progression. The current results will encourage further 
studies on the activity and mechanism of the terpene quinones, leading to the fragment 
based drug design. Time-lapse imaging of HeLa/Fucci2 cells is a promising 
experimental means to identify natural products exhibiting biological activity concerned 
with cell cycle progression, offering opportunities for the development of new natural 
product derived antitumor agents.  
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4.2.4. Experimental Section 
4.2.4.1. General Experimental Procedures. 
UV spectra were measured on a Shimadzu Biospec 1600. NMR spectra were recorded 
on a JEOL alpha 600 NMR spectrometer. Chemical shifts were referenced to solvent 
peaks: δH7.24 and δc 77.0 for CDCl3. ESI mass spectra were measured on a JEOL 
JMS-T100LC. HPLC was carried out on the Shimadzu LC 20AT with a SCL-10Avp 
controller and a SPD-10Avp detector. Time-lapse imaging of cells was conducted on the 
Essen bioscience IncuCyteZoom. DNA content was analyzed by flow cytometer BD 
FACSJAZZ. 
 
4.2.4.2. Animal Material. 
The sponge S09-1061-02 was collected at Miyako sea-knoll, southwestern Japan, at a 
depth of 415 m, during a cruise of R/V Natsushima, by using the Remotely Operated 
Vehicle ‘Hyper-Dolphin’ in October 2009. The sponge S13-013 was collected at the sea 
near Amami-Ohshima during the cruise of Toyoshio-maru in 2013. 
 
4.2.4.3. Extraction and Isolation of metachromins. 
The frozen marine sponge (80 g, wet weight) was homogenized and extracted with 
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EtOH (250 mL x 2) and mixture of MeOH and CHCl3 (1:1, 300 mL). The combined 
extracts were evaporated in vacuo and partitioned between H2O and CHCl3. The organic 
layer was evaporated and partitioned between 90% MeOH and n-hexane. The aqueous 
MeOH layer was concentrated and subjected to the ODS column chromatography 
eluting with 50% MeOH, 70% MeOH, 90% MeOH, and CHCl3/MeOH/H2O (14:6:1). 
The 90% MeOH eluate was concentrated and purified by RP-HPLC (Cosmosil MS-II; 
20 x 250 mm) with 80% MeCN containing 0.5% AcOH to afford 4-2 (8.5 mg), 4-4, 4-5 
and mixture of 4-1 and 4-3 (500 mg). One part of the mixture was further purified with 
RP-HPLC (Cosmosil MS-II; 20 mm x 250 mm) with 80% MeCN containing 0.5% 
AcOH to afford 4-1 and 4-3. 
4.2.4.3.1. Metachromin X (4-1): dark orange solid; UV (MeOH) λmax(log ε) 210 (16 
000), 287 (16 000), 424 (490); 1H NMR and 13C NMR data (CDCl3), see Table 1; 
HRESIMS m/z[M+Na]+381.2051 (calcd for C22H30O4Na
+, 381.2042) 
4.2.4.3.2. Metachromin Y (4-2): red solid; UV (MeOH) λmax(log ε) 214 (9 900), 258 (6 
000), 307 (7 100), 485 (420); 1H NMR and 13C NMR data (CDCl3), see Table 1; 
HRESIMS m/z[M+Na]+ 379.1869 (calcd for C22H28O4Na
+, 379.1885). The accurate 
optical rotation could not be measured because the UV absorption of 2 interfered with 
the D line of a Na light. 
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4.2.4.4. Extraction and Isolation of 5-epi-isospongiaquinone. 
The frozen marine sponge S13-013 (100 g, wet weight) was extracted with EtOH (300 
m x 2) and mixture of MeOH/CHCl3 (1:1, 300 mL). The combined extracts were 
combined and concentrated in vacuo, then partitioned between H2O and CHCl3. The 
organic layer was further partitioned between 90% MeOH and n-hexane. The 90 % 
layer was concentrated and subjected to ODS column chromatography eluting with 50% 
MeOH, 70% MeOH, 90% MeOH, and CHCl3/MeOH/H2O (14:6:1). The MeOH fraction 
was purified by ODS HPLC (Cosmosil AR-II; 20 mm x 250 mm) eluting with 78% 
MeCN to afford 35 mg of 5-epi-isospongiaquinone (4-6). 
 
4.2.4.5. Preparation of 4-7 from 4-1. 
To a solution of compound 4-1 (12.5 mg) in MeCN (3.5 mL) was added K2CO3 (240 
mg) and MeI (100 μL). The reaction mixture was refluxed for 2 h. The reaction mixture 
was filtrated and dried in vacuo. Si gel column chromatography (n-hexane/EtOAc = 
3:1) afforded methyl ether of 4-1 (12.5 mg). The methylated compound (10 mg) was 
dissolved in pyridine (3 mL) and heated at 110 oC overnight. The reaction mixture was 
concentrated in vacuo. To a solution of the resultant oil (10 mg) in MeCN (0.5 mL) was 
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added K2CO3 (100 mg) and MeI (60 μL) and refluxed for 3 h, then filtered and dried in 
vacuo. RP-HPLC purification afforded the racemic mixture of 7 (2.3 mg); 1H NMR 
(CDCl3); δ 6.64 (d, 10.0 Hz, 1H), 6.43 (s, 1H), 5.67 (d, 10.0 Hz, 1H), 3.82 (s, 3H), 3.80 
(s,3H), 3.74 (s, 3H), 2.11 (t, 8.8 Hz, 2H), 1.83 (t, 6.2, 2H), 1.74-1.70 (m, 3H), 1.51-1.49 
(m, 3H), 1.50 (s, 3H), 1.44 (s, 3H), 1.35 (m, 2H), 0.94 (s, 3H), 0.88 (s, 3H); LRESIMS 
m/z 387.6 (M+H)+. 
 
4.2.4.6. Preparation of 4-7 from 4-2. 
 To a solution of 4-2 (1.2 mg) in EtOAc (50 μL), H2O (0.5 mL), and Et2O (0.5 mL) was 
added Na2S2O4 (20 mg). The reaction mixture was stirred vigorously for 20 min at room 
temperature. The reaction mixture was extracted with Et2O (1 mL x 2) and dried over 
Na2SO4 and N2 gas flushing. The resultant solid was then dissolved in DMSO (0.8 mL), 
and added K2CO3 (50 mg) and MeI (50 μL). The reaction mixture was stirred for 1h 
under the N2 gas. The reaction mixture was filtered and dried in vacuo, and purified by 
RP-HPLC to afford compound 4-7 (0.9 mg).1H NMR data and LRESIMS were 
superimposable on those of 4-7 prepared from 4-1. 
 
4.2.4.7. Cell Culture and MTT assay 
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HeLa/Fucci2 cells were cultured in DMEM (Wako) supplemented with 10% fetal 
bovine serum, and 100 units/mL penicillin and 0.1 mg/mL streptomycin at 37 ºC under 
an atmosphere of 5% CO2. To each well of a 96-well microplate containing 200 μL of 
tumor cell suspension (1 x 104 cells/mL) was added a sample after overnight 
preincubation, and the plate was incubated for 72 h. After addition of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) saline solution (1 
mg/mL, 50 μL) to each well, the plate was incubated for 3 h. After the incubation, the 
supernatant was discarded and DMSO (150 μL) was added. The absorbance was 
measured to determine IC50 values. 
 
4.2.4.8. Time-Lapse Imaging of HeLa/Fucci2 Cells 
HeLa/Fucci2 cells were grown in FluoroBrite DMEM media (life technologies) 
supplemented with 10% fetal bovine serum, 4 mM L-glutamine, 100 units/mL penicillin 
and 0.1 mg/mL streptomycin. HeLa/Fucci2 cells were grown on six-well plates 
(100,000 cells in control groups and 300,000 cells in compound treated cells) and 
incubated for three days at 37 ºC with either 20 μg/mL of 4-1, 4-2, 4-6, or 0.2% MeOH.  
 
4.2.4.9. Cell cycle analysis of HeLa/Fucci2 cells by flow cytometer. 
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HeLa/Fucci2 cells were seeded in 6 well plate at concentrations of 10,000 cells/mL in 
control group and 30,000 cells/mL in 4-1 treated cells. After two days incubation with 
0.2% of MeOH or 20 μg/mL of 4-1, the cells were treated with 0.25% trypsin and 
collected. Cells were rinsed with PBS twice, and stained with hypotonic PI solution (50 
μg/mL of PI, 0.1% of sodium citrate, 0.2% of NP-40, 0.25 mg/mL of RNase in distilled 
water). 20,000 cells were analyzed by flow cytometer at 585 nm. 
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Figure S4-2-1. 1H NMR spectrum of 4-1 
 
Figure S4-2-2. 13C NMR spectrum of 4-1 
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Figure S4-2-3. COSY spectrum of 4-1 
 
Figure S4-2-4. HSQC spectrum of 4-1 
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Figure S4-2-5. HMBC spectrum of 4-1 
 
Figure S4-2-6. NOESY spectrum of 4-1 
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Figure S4-2-7. 1H NMR spectrum of 4-2 
 
Figure S4-2-8. 13C NMR spectrum of 4-2 
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Figure S4-2-9. COSY spectrum of 4-2 
 
Figure S4-2-10. HSQC spectrum of 4-2 
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Figure S4-2-11. HMBC spectrum of 4-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4-2-12. Photographs of unidentified marine sponges S09-1061-02 (left) and S13-013 (right). 
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Chapter 5. Conclusion 
 
 
 
 Marine organisms produce a vriety of secondary metabolites, and such marine 
natural products are important sources of the drug leads and research tools. Recent 
dramatic advances of scientific technologies are disclosing the molecular mechanisms, 
biosynthetic genes, and the true producers of bioactive marine natural products. 
Fundamental part of these translational researches is the discovery of bioactive 
compounds from the marine organisms. 
In this study, we have investigated novel bioactive compounds from deep-sea 
marine sponges, and discovered several novel bioactive sponge metabolites by using 
cell-based assays. 
We discovered two groups of acetylene compounds, (-)-durynes and 
miykosynes from the same marine sponge Petrosia sp. In combination of NMR 
spectroscopy and FAB-MS/MS measurements their chemical structures were 
determined. In particular, miyakosyne A was highlighted in the discussion over the 
determination of the absolute configuration at isolated chiral center.  
Potent cytotoxic macrolide lactams, poecillastrins, were discovered from an 
unidentified marine sponge S09-1060-01. These molecules have complicated structures 
and a number of chiral centers. In spite of the limited amount of compounds, we partly 
assigned the relative configurations. Poecillastrins exhibited unique bioactivity and they 
are worthy to explore for their therapeutic potentials. 
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Fluorescent time-lapse imaging of HeLa/Fucci2 was applied for the evaluation 
of biological activities of marine natural products. This assay enabled us to select 
samples that induced cell cycle arrest and/or cellular morphological changes, resulting 
in the isolation of several active compounds. Metachromins are the first marine natural 
products identified through the time-lapse imaging assay of HeLa/Fucci2 cells. 
Structure activity relationship of these terpene quinones revealed that 
2-hydroxy-5-methoxy-1,4-benzoquinone moiety is essential for inducing mitotic arrest. 
 
By this study, we have confirmed that marine sponges are rich sources of 
bioactive metabolites. Investigation of novel marine natural products through cell-based 
assays will lead to the discovery of therapeutically promising metabolites. 
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